Syna
·
·
Guide Heightmaxxing 202 (2 Viewers)
Guide
Heightmaxxing 202
- Thread starter fent
- Start date
- Joined
- Dec 30, 2025
- Posts
- 5,934
- Reputation
- 17,809
lets just make a new gc then
Mandy
It’s just Mandy,baby💋
- Joined
- Nov 11, 2025
- Posts
- 1,574
- Reputation
- 4,322
I’m monamolester999 add me
- Joined
- Dec 30, 2025
- Posts
- 5,934
- Reputation
- 17,809
done
Certifedsubhuman
I love futa
- Joined
- Nov 2, 2025
- Posts
- 822
- Reputation
- 1,035
haven’t read but looks very promising I’m mirin
FoidSlayer
we will all ascend
- Joined
- Dec 15, 2025
- Posts
- 8,046
- Reputation
- 21,454
I hate him
Telmisartan
Iron
- Joined
- Mar 26, 2026
- Posts
- 233
- Reputation
- 497
Donated 1 rep since I'm a broke ass nigga but high effort, mirinHeightmaxxing 202
By: Fent
____________________________________________________________________
Table of Contents:
FGFR3 inhibitors
CXXC5 inhibitors
SAG's
Vosoritide
Foxo4-dri
AAS for height growth
-Winstrol
-Anavar
-Halotestin
Tamoxifen
Socs2 inhibition
PTHrP analogues
SCO240
____________________________________________________________________
FGFR3 Inhibitors
What are FGFR3 Inhibitors
View attachment 45160
FGFR3 inhibitors are drugs that block the Fibroblast Growth Factor Receptor 3 protein FGFR3 normally acts like a brake on bone growth in the growth plates (the cartilage areas at the ends of long bones that allow you to get taller during childhood and adolescence). By inhibiting FGFR3, these drugs reduce that braking effect, allowing chondrocytes to proliferate and mature more freely. This leads to increased linear bone growth and greater height velocity especially in conditions like achondroplasia where the receptor is overactive due to a genetic mutation.
Types of FGFR3 inhibitors
•Infigratinib
•Erdafitinib
•Tyra-300 (dabogratinib)
•Loxo435
Infigratinib
Orally bioavailable, FGFR1-3 selective ATP-competitive TKI. It binds the ATP pocket of FGFR1, FGFR2, and FGFR3 (with much weaker activity on FGFR4 and VEGFR2). This dual inhibition hits both MAPK (hypertrophy) and STAT1 (proliferation) pathways downstream of FGFR3.
TL;DR
Once daily oral infigratinib (0.25 mg/kg) gave +1.74 cm/year (LS mean) or +2.10 cm/year extra annualized height velocity (AHV) vs placebo at 52 weeks. Absolute AHV reached 5.96 cm/year (highest reported in any ACH randomized trial). First drug to show statistically significant improvement in upper-to-lower body proportionality. Well tolerated; no FGFR1/2-related AEs or serious treatment-related events.
TL;DR
In ACH kids, highest dose produced +2.50 cm/year change in AHV from baseline at 18 months, +0.54 height Z-score, and improved proportionality (upper:lower ratio –0.12). Sustained effect, good safety.
TL;DR
Low dose infigratinib increased femur length, growth plate proliferative zone, and corrected disproportionate growth in Fgfr3 mutant mice.
Erdafitinib
Oral pan-FGFR (FGFR1-4) TKI. First FDA-approved pan-FGFR inhibitor (2019, for FGFR-altered urothelial cancer). Most potent against FGFR1, followed by FGFR3 > FGFR4 > FGFR2. Less selective than the others, so more off-target potential. (Not the best)
TL;DR
Pre-pubescent child with FGFR1-mutated glioma on erdafitinib showed rapid long-bone overgrowth, kyphoscoliosis, and spinal deformities within months
TL;DR
Cancer patients on erdafitinib had growth-factor and sex steroid independent acceleration of linear growth via FGFR3 inhibition. Proves the mechanism works for height but also carries severe risk.
Tyra-300
Oral, highly isoform-selective FGFR3 TKI (first-in-class FGFR3-selective). Designed with TYRA’s SNÅP platform to potently hit FGFR3 while sparing FGFR1/2/4 to minimize off-target toxicity. Once daily small molecule.
TL;DR
n wild-type mice + two FGFR3-driven models (ACH and hypochondroplasia), TYRA-300 significantly increased long-bone length (femur +3.7–5%, tibia +3.75–6%, etc.), nasoanal length, foramen magnum size, and improved skeletal proportionality and bone quality. First clear data showing FGFR3-selective inhibition works even in normal genetics. (Huge)
Loxo435
Oral, highly isoform-selective FGFR3 inhibitor (potent small-molecule TKI). Engineered by LOXO Oncology / Eli Lilly (goat) to maximize FGFR3 potency while minimizing off-target effects on other FGFRs and kinases for better safety.
There isnt too many studies i thought were worth showing however it looks promising alongside tyra-300 as a selective FGFR3 Inhibitor.
Biggest Con With Each Inhibitor:
Infigratinib:
• hyperphosphatemia
Erdafitinib:
•Rapid overgrowth (if retarded), Slipped capital femoral epiphysis and growth plate changes + premature fusion
Tyra-300:
•Unknown, as there is not enough studies+ pricing
Loxo435:
•same with tyra
CXXC5 Inhibitors
CXXC5
View attachment 45161
Acts as a negative regulator of human height by accelerating growth plate senescence and limiting longitudinal bone growth. It functions as a feedback inhibitor of the Wnt/β-catenin signaling pathway, which is paramount for maintaining chondrocyte proliferation and delaying senescence in the epiphyseal growth plates.
Induced by Wnt signaling itself and by estrogen (via estrogen receptor alpha), CXXC5 interacts with Dishevelled (DVL) to suppress β-catenin activity, thereby reducing chondrocyte proliferation, hypertrophy, and overall bone elongation.
In mouse models, CXXC5 knockout results in delayed growth plate senescence, increased tibial length, expanded proliferative and hypertrophic zones, and higher bone mass due to enhanced Wnt signaling. Pharmacological disruption of the CXXC5–DVL interaction has been shown to promote bone growth in preclinical studies, suggesting potential therapeutic applications for short stature caused by premature growth plate closure
The only CXXC5 inhib i think worth talking about is KY19382
KY19382
View attachment 45180
A small-molecule dual inhibitor that blocks CXXC5 (a protein that speeds up growth plate senescence/aging, which stops you from growing taller) from binding to dishevelled, while also inhibiting GSK3β.
This strongly activates the Wnt/β-catenin pathway inside growth-plate cartilage cells, delaying senescence, boosting chondrocyte proliferation, and keeping the growth plates active longer so bones can keep lengthening
Administration:
• Transdermally
- (not preferred imo)
• Subcutaneous Injection
“A functionally improved indirubin derivative, KY19382, elongated tibial length through delayed senescence and further activation of the growth plate in adolescent mice.”
Directly from the abstract; the full paper also states:
“Our results showed that KY19382 effectively increased the longitudinal growth of tibiae by delaying growth plate senescence through the accompanying promotion of chondrocyte proliferation and differentiation.”
Only con is theres no data in long term use
SAG21k and Purmorphamine
SAG21k and Purmorphamine
Small drug like molecules that directly switch on the Smoothened (SMO) receptor in the Hedgehog (Hh/Ihh/Shh) signaling pathway.
In the growth plates of growing bones, they completely bypass the normal control step where the Ihh signal inhibits Patched. This instantly activates Gli transcription factors.
The Result:
more epiphyseal skeletal stem cells (epSSCs) multiply in the resting zone, cartilage cells (chondrocytes) grow faster and form bigger clusters, a special environment is created that blocks Wnt signals to keep stem cells active, and the process of turning cartilage into bone speeds up.
Overall, this makes the growth plates thicker and leads to greater longitudinal bone lengthening
TL;DR
Systemic SAG21k (5 mg/kg/day IP for 7 days) in a mouse bone-defect model strongly enhanced early chondrogenesis via SHH pathway activation, creating more cartilage template that later ossified into greater bone
Cons:
•Most likely cancer causing due to hedgehog pathway overactivation
•Price
•Sourcing
•You need a special delivery method for it
However, if you can source, afford and use it strategically so you dont get cancer, one of the greatest heightmaxx compounds
Vosoritide + CNP
What is CNP
CNP is a natural peptide hormone produced locally right inside your growth plates by chondrocytes (the cartilage cells that turn into bone CNP’s job is promoting endochondral bone growth (the exact process that makes your long bones femurs, tibias, etc longer during childhood/adolescence.)
CNP binds to its receptor NPR-B on chondrocytes, this ramps up intracellular cGMP (a signaling molecule).
cGMP then inhibits the MAPK/ERK pathway
Chondrocytes proliferate more, mature faster (hypertrophy), and produce more bone matrix and longer bones and increased height velocity.
Vosoritide
View attachment 45175
Vosoritide is a lab-made, longer lasting analog of CNP (39-amino-acid version engineered to resist quick breakdown). It’s given as a daily subcutaneous injection and is the first (and currently only) approved drug that directly harnesses this pathway for ACH. Vosoritide mimics CNP, binds NPR-B, raises cGMP, and counteracts FGFR3 signaling downstream (without touching the FGFR3 receptor itself meaning it is indirect).
TLDR 121 ACH kids (5–18 years). Vosoritide 15 µg/kg daily --> +1.57 cm/year extra AGV vs placebo (5.39 vs 3.81 cm/year at 52 weeks). Also +0.28 height Z-score.
Degrades VERY fast
Expensive compared to something like erda or infig.
FOXO4-DRI
FOXO4-DRI
View attachment 45172
FOXO4-DRI is a synthetic senolytic cell-penetrating peptide designed to selectively eliminate senescent cells (cells that stop dividing but secrete harmful inflammatory factors while healthy non-senescent cells are largely spared as it was designed to be selective)
How could it be used for height?
Growth plates naturally stop working (and height growth ends) because chondrocytes progressively enter senescence: they stop proliferating, secrete harmful inflammatory signals (the senescence-associated secretory phenotype, or SASP), and create a toxic microenvironment that further slows nearby healthy cells. This depletes the pool of resting-zone stem cells (epSSCs), shrinks the proliferative zone, reduces hypertrophic chondrocyte activity, and eventually leads to growth-plate thinning and fusion. Senescence is the main “programmed brake” on adult height.
FOXO4-DRI is designed to exploit a vulnerability unique to senescent cells: it disrupts the protective binding between FOXO4 and p53. In senescent chondrocytes (which rely heavily on this interaction to survive), this causes p53 to exit the nucleus, move to mitochondria, and trigger apoptosis (programmed cell death)
In Short
It would remove the accumulated senescent chondrocytes that are secreting SASP factors (IL-6, MMPs, etc.). Reduce inflammation and paracrine inhibition in the growth plate
Delay the overall “cell-counting” timer of senescence and postpone growth plate closure.
And allows epiphyseal skeletal stem cells and proliferative chondrocytes to expand, form longer columns, and maintain active endochondral ossification
However, I wouldnt personally take it.
AAS for height growth
Anavar:
(oxandrolone)
View attachment 45179
Mildest oral anabolic of the three. Temporarily boosts linear growth in some medical settings but advances bone age disproportionately. Lowest relative risk among the three for rapid closure, yet still causes net loss or no gain in adult height potential in normal teens.
Winstrol:
View attachment 45177
Animal data shows direct effects on growth plate chondrocytes
Halo:
(halotestin/fluoxymesterone)
View attachment 45178
Strongest/most potent androgen of the three (highly liver-toxic). Fastest bone maturation effect; FDA labels explicitly warn that androgens like this accelerate epiphyseal closure without compensatory linear growth in children. Highest risk of stunting height (if retarded)
TL;DR
Anavar increased height velocity but accelerated skeletal age more; some children lost predicted adult height (1.5–7.5 cm)
TL;DR
Winstrol affected proliferation of growth plate cells in adolescent rats (via estrogen receptor pathways). Shows direct impact on the growth plate but in a suppressed puberty model
TL;DR
Low-dose Halo increased growth velocity but required careful bone age monitoring. Final height exceeded predictions only in delayed cases
In conclusion
anavar has the most evidence for increased height velocity (despite me only showing one study for each).
however you have to be careful to not cause alot of bone maturation which isnt too hard. Best of luck
When you take any AAS even at a low dose the drug travels through your bloodstream and reaches the growth plates. There it binds directly to androgen receptors on the chondrocytes, the cartilage cells responsible for making new bone. These androgen receptors do not care if the dose is high or low; they simply respond to the presence of the molecule. Their job is to accelerate terminal differentiation, basically telling the chondrocytes to stop dividing and to mature faster into bone.
Therefore it is utter copeDexter thanks
for the help.
Tamoxifen
Tamoxifen:
View attachment 45173
selective estrogen receptor modulator (SERM), a drug that binds to estrogen receptors (mainly ERα and ERβ) and can act as either an estrogen blocker (antagonist) or estrogen mimic (agonist) depending on the tissue. It is FDA-approved primarily for treating and preventing estrogen receptor-positive breast cancer in adults, and it is also used off label for conditions like gynecomastia
How Tamoxifen Works
Tamoxifen competes directly with estradiol (E2) for binding to estrogen receptors in target cells
In growth-plate chondrocytes (cartilage cells responsible for bone lengthening), it can exert anti-estrogenic effects by inhibiting specific downstream signaling pathways triggered by E2, such as protein kinase C (PKC). This modulates chondrocyte differentiation and profileration
TL;DR
7 short pubertal boys (average age ~15) treated with tamoxifen (twice daily for 6 months–4 years; some also on GH). Tamoxifen significantly slowed skeletal maturation and increased predicted adult height by 4 inches (from ~5'6" to ~5'10") with no negative effects on sexual maturation or puberty progression
However authors called for larger prospective studies to confirm if this translates to actual final height gain
TL;DR
In vivo study in young male rats given clinically relevant doses for 4 weeks (followed by 14-week recovery). Tamoxifen caused persistent shorter tibia and reduced cortical bone size/strength, increased chondrocyte apoptosis, narrowed growth plates, and lowered serum IGF-1 levels
Socs2 inhibition
SOCS2:
(Suppressor of Cytokine Signaling 2)
View attachment 45174
Is a protein encoded by the SOCS2 gene in humans. It belongs to the SOCS family of intracellular proteins that act as negative feedback regulators of cytokine signaling, primarily through the JAK/STAT pathway
SOCS2 is a key negative regulator of growth hormone (GH) signaling. It binds to the phosphorylated GH receptor (GHR), promotes its ubiquitination and degradation (via the ECS ubiquitin ligase complex), and thereby dampens downstream STAT5 activation and IGF-1 production. This limits the anabolic and growth-promoting effects of GH/IGF-1
Which basically means SOCS2 is an inhibitor of GH Because SOCS2 inhibits GH signaling, reducing or blocking SOCS2 function removes this brake. This leads to enhanced GH receptor sensitivity, prolonged STAT5 signaling, higher local and systemic IGF-1, and increased linear bone growth. They are kinda like FGFR3 inhibitors.
Pros
•Significant linear growth enhancement
•Amplifies exogenous GH
•Targeted and reversible
Cons
•Metabolic risks from chronic GH/IGF-1 hyper-signaling: Potential insulin resistance,ect
IGF-1 is mitogenic; SOCS2 has complex roles in cancer (sometimes tumor-suppressive, sometimes pro-tumor in specific tissues)
•Potential organ enlargement
•Not too many ways to actually inhibit
TL;DR
mice grew 30–40% larger than wild-type, increased body weight, long-bone length, and proportional enlargement of most organs
TL;DR
Naturally occurring deletion of SOCS2 increased growth significantly however shortened lifespan in some mice
TL;DR
Mutation in SOCS2 linked to gigantism (increased height/weight) in human model
PTHrP analogues
PTHrP analogues:
View attachment 45171
Synthetic peptides that mimic parathyroid hormone-related protein (PTHrP), a key local regulator of the growth plate. The main clinically available ones are abaloparatide (Tymlos; a modified PTHrP(1-34) analogue) and teriparatide (Forteo; recombinant human PTH(1-34)). Both bind and activate the same receptor (PTH1R) that native PTHrP uses in chondrocytes, but they are given as daily subcutaneous injections.
In the epiphyseal growth plate, PTHrP is produced locally by resting-zone chondrocytes (including skeletal stem cells). It acts via PTH1R to Keep chondrocytes in the proliferative state, delay their maturation into hypertrophic cells and maintain the Ihh–PTHrP feedback loop that controls the pace of endochondral ossification
Intermittent (once-daily) dosing of PTHrP/PTH analogues mimics this natural signaling in a pulsed way that strongly stimulates bone formation meaning these compounds would:
•Expand the proliferative and hypertrophic zones
Increase chondrocyte columns and cartilage thickness
•Prolong active growth before senescence/closure
In short increasing height
Abalo and Teri Comparison:
Abalo pros:
•Designed to copy PTHrP’s natural growth-plate role more closely
•Potentially cleaner anabolic effect with less unwanted resorption or calcium spikes
•Rat data suggest stronger stimulation of cartilage thickness and site-specific bone lengthening
Abalo cons:
•Far less real-world pediatric data
osteosarcoma risk as seen in high dose rat studies
Teri pros:
•Decades more safety/efficacy data in humans
Proven to stimulate longitudinal growth in animal models
Teri cons:
•more resorption and higher hypercalcemia risk
Less selective
In conclusion abalo would be the better choice here however it has alot less research so, its down to preference.
SCO240
SCO240:
An oral small-molecule antagonist of somatostatin receptor type 5 (SSTR5). It is a first in class compound designed to stimulate endogenous GH secretion
from the pituitary gland
Somatostatin normally inhibits GH release by binding to SSTR5 on pituitary somatotroph cells. SCO-240 blocks this receptor selectively, removing the inhibition and allowing the body to release more of its own GH in a more physiological (pulsatile) pattern — without affecting other pituitary hormones (prolactin, TSH, ACTH, FSH, LH).
By boosting natural GH secretion, SCO-240 increases downstream IGF-1 production, which directly promotes chondrocyte proliferation and hypertrophy leading to increased growth velocity.
•Oral (convenience)
•Highly selective for GH
•Physiological GH release: mimics natural pulsatile pattern more closely than injected rhGH.
•Only phase 1 data in healthy adults; no published efficacy or height data in children with GHD or short stature yet.
•Basic GH excess risks (insulin resistance ect)
•Sourcing + Prices
•Limited data
TL;DR
Caused robust, dose-dependent GH secretion (comparable to therapeutic rhGH levels) with no effect on other pituitary hormones, insulin, or GLP-1.
Growth Plates
Resting Zone
This is the top layer of the growth plate, right near the end of the bone. The cells here are mostly stagnant and don’t divide much. They act like a stock of spare cartilage cells. Their job is to slowly supply new cells to the layers below when needed.
Proliferating Zone
This is the busy factory zone. The cartilage cells divide quickly and stack up in neat columns, like coins piled on top of each other. Every time they multiply, they add a bit more length to the bone. This is where most of the actual growth in height happens. It’s the most active part of the growth plate.
Hypertrophic Zone
In this zone, the cells stop dividing and start getting much bigger. As they grow larger, they help push the bone longer. Then they prepare the area by making the cartilage matrix harder. Eventually the cells die off, and the hardened cartilage gets replaced by real bone. This is the last step before the cartilage turns into solid bone.
____________________________________________________________________
Conclusion:
Leave a rep if you enjoyed
Until Next Time
nineteen
tmpll
XvideosDemon
antifoidaction
carbon
FaZe_Kjetil00
fgfr3
LifeEnjoyer
Razi
Amygdala B Biomaxx
blank
coloringhalo
FoidSlayer H hideandseek
Michael b
Mirin
Mtn_hell
Peace
Tismo
determinism
kanyewestlover66
AlexBrown3434
slogxER
Skulloute
Holy
sensitive sapphire
Hexum
Marlboro
syna
Histy
Mandy
Beyondthegrave
Includings
hoodsickle
iloveyou
Hyporoxin
Jester4Foids
i_blame_oxytocin
User
VelocityAnt
Judenbänker M makeaway
Nardicus102
thuuk
fentasticfob
guilty
4pfl
atrophicpyra
Brian
sneakyalex7
bob08674
Monstrum (love u bhai)
.Raze
Sorb
Iron
- Joined
- Apr 10, 2026
- Posts
- 19
- Reputation
- 6
Heightmaxxing 202
By: Fent
____________________________________________________________________
Table of Contents:
FGFR3 inhibitors
CXXC5 inhibitors
SAG's
Vosoritide
Foxo4-dri
AAS for height growth
-Winstrol
-Anavar
-Halotestin
Tamoxifen
Socs2 inhibition
PTHrP analogues
SCO240
____________________________________________________________________
FGFR3 Inhibitors
What are FGFR3 Inhibitors
View attachment 45160
FGFR3 inhibitors are drugs that block the Fibroblast Growth Factor Receptor 3 protein FGFR3 normally acts like a brake on bone growth in the growth plates (the cartilage areas at the ends of long bones that allow you to get taller during childhood and adolescence). By inhibiting FGFR3, these drugs reduce that braking effect, allowing chondrocytes to proliferate and mature more freely. This leads to increased linear bone growth and greater height velocity especially in conditions like achondroplasia where the receptor is overactive due to a genetic mutation.
Types of FGFR3 inhibitors
•Infigratinib
•Erdafitinib
•Tyra-300 (dabogratinib)
•Loxo435
Infigratinib
Orally bioavailable, FGFR1-3 selective ATP-competitive TKI. It binds the ATP pocket of FGFR1, FGFR2, and FGFR3 (with much weaker activity on FGFR4 and VEGFR2). This dual inhibition hits both MAPK (hypertrophy) and STAT1 (proliferation) pathways downstream of FGFR3.
TL;DR
Once daily oral infigratinib (0.25 mg/kg) gave +1.74 cm/year (LS mean) or +2.10 cm/year extra annualized height velocity (AHV) vs placebo at 52 weeks. Absolute AHV reached 5.96 cm/year (highest reported in any ACH randomized trial). First drug to show statistically significant improvement in upper-to-lower body proportionality. Well tolerated; no FGFR1/2-related AEs or serious treatment-related events.
TL;DR
In ACH kids, highest dose produced +2.50 cm/year change in AHV from baseline at 18 months, +0.54 height Z-score, and improved proportionality (upper:lower ratio –0.12). Sustained effect, good safety.
TL;DR
Low dose infigratinib increased femur length, growth plate proliferative zone, and corrected disproportionate growth in Fgfr3 mutant mice.
Erdafitinib
Oral pan-FGFR (FGFR1-4) TKI. First FDA-approved pan-FGFR inhibitor (2019, for FGFR-altered urothelial cancer). Most potent against FGFR1, followed by FGFR3 > FGFR4 > FGFR2. Less selective than the others, so more off-target potential. (Not the best)
TL;DR
Pre-pubescent child with FGFR1-mutated glioma on erdafitinib showed rapid long-bone overgrowth, kyphoscoliosis, and spinal deformities within months
TL;DR
Cancer patients on erdafitinib had growth-factor and sex steroid independent acceleration of linear growth via FGFR3 inhibition. Proves the mechanism works for height but also carries severe risk.
Tyra-300
Oral, highly isoform-selective FGFR3 TKI (first-in-class FGFR3-selective). Designed with TYRA’s SNÅP platform to potently hit FGFR3 while sparing FGFR1/2/4 to minimize off-target toxicity. Once daily small molecule.
TL;DR
n wild-type mice + two FGFR3-driven models (ACH and hypochondroplasia), TYRA-300 significantly increased long-bone length (femur +3.7–5%, tibia +3.75–6%, etc.), nasoanal length, foramen magnum size, and improved skeletal proportionality and bone quality. First clear data showing FGFR3-selective inhibition works even in normal genetics. (Huge)
Loxo435
Oral, highly isoform-selective FGFR3 inhibitor (potent small-molecule TKI). Engineered by LOXO Oncology / Eli Lilly (goat) to maximize FGFR3 potency while minimizing off-target effects on other FGFRs and kinases for better safety.
There isnt too many studies i thought were worth showing however it looks promising alongside tyra-300 as a selective FGFR3 Inhibitor.
Biggest Con With Each Inhibitor:
Infigratinib:
• hyperphosphatemia
Erdafitinib:
•Rapid overgrowth (if retarded), Slipped capital femoral epiphysis and growth plate changes + premature fusion
Tyra-300:
•Unknown, as there is not enough studies+ pricing
Loxo435:
•same with tyra
CXXC5 Inhibitors
CXXC5
View attachment 45161
Acts as a negative regulator of human height by accelerating growth plate senescence and limiting longitudinal bone growth. It functions as a feedback inhibitor of the Wnt/β-catenin signaling pathway, which is paramount for maintaining chondrocyte proliferation and delaying senescence in the epiphyseal growth plates.
Induced by Wnt signaling itself and by estrogen (via estrogen receptor alpha), CXXC5 interacts with Dishevelled (DVL) to suppress β-catenin activity, thereby reducing chondrocyte proliferation, hypertrophy, and overall bone elongation.
In mouse models, CXXC5 knockout results in delayed growth plate senescence, increased tibial length, expanded proliferative and hypertrophic zones, and higher bone mass due to enhanced Wnt signaling. Pharmacological disruption of the CXXC5–DVL interaction has been shown to promote bone growth in preclinical studies, suggesting potential therapeutic applications for short stature caused by premature growth plate closure
The only CXXC5 inhib i think worth talking about is KY19382
KY19382
View attachment 45180
A small-molecule dual inhibitor that blocks CXXC5 (a protein that speeds up growth plate senescence/aging, which stops you from growing taller) from binding to dishevelled, while also inhibiting GSK3β.
This strongly activates the Wnt/β-catenin pathway inside growth-plate cartilage cells, delaying senescence, boosting chondrocyte proliferation, and keeping the growth plates active longer so bones can keep lengthening
Administration:
• Transdermally
- (not preferred imo)
• Subcutaneous Injection
“A functionally improved indirubin derivative, KY19382, elongated tibial length through delayed senescence and further activation of the growth plate in adolescent mice.”
Directly from the abstract; the full paper also states:
“Our results showed that KY19382 effectively increased the longitudinal growth of tibiae by delaying growth plate senescence through the accompanying promotion of chondrocyte proliferation and differentiation.”
Only con is theres no data in long term use
SAG21k and Purmorphamine
SAG21k and Purmorphamine
Small drug like molecules that directly switch on the Smoothened (SMO) receptor in the Hedgehog (Hh/Ihh/Shh) signaling pathway.
In the growth plates of growing bones, they completely bypass the normal control step where the Ihh signal inhibits Patched. This instantly activates Gli transcription factors.
The Result:
more epiphyseal skeletal stem cells (epSSCs) multiply in the resting zone, cartilage cells (chondrocytes) grow faster and form bigger clusters, a special environment is created that blocks Wnt signals to keep stem cells active, and the process of turning cartilage into bone speeds up.
Overall, this makes the growth plates thicker and leads to greater longitudinal bone lengthening
TL;DR
Systemic SAG21k (5 mg/kg/day IP for 7 days) in a mouse bone-defect model strongly enhanced early chondrogenesis via SHH pathway activation, creating more cartilage template that later ossified into greater bone
•Most likely cancer causing due to hedgehog pathway overactivation
•Price
•Sourcing
•You need a special delivery method for it
However, if you can source, afford and use it strategically so you dont get cancer, one of the greatest heightmaxx compounds
Vosoritide + CNP
What is CNP
CNP is a natural peptide hormone produced locally right inside your growth plates by chondrocytes (the cartilage cells that turn into bone CNP’s job is promoting endochondral bone growth (the exact process that makes your long bones femurs, tibias, etc longer during childhood/adolescence.)
CNP binds to its receptor NPR-B on chondrocytes, this ramps up intracellular cGMP (a signaling molecule).
cGMP then inhibits the MAPK/ERK pathway
Chondrocytes proliferate more, mature faster (hypertrophy), and produce more bone matrix and longer bones and increased height velocity.
Vosoritide
View attachment 45175
Vosoritide is a lab-made, longer lasting analog of CNP (39-amino-acid version engineered to resist quick breakdown). It’s given as a daily subcutaneous injection and is the first (and currently only) approved drug that directly harnesses this pathway for ACH. Vosoritide mimics CNP, binds NPR-B, raises cGMP, and counteracts FGFR3 signaling downstream (without touching the FGFR3 receptor itself meaning it is indirect).
TLDR 121 ACH kids (5–18 years). Vosoritide 15 µg/kg daily --> +1.57 cm/year extra AGV vs placebo (5.39 vs 3.81 cm/year at 52 weeks). Also +0.28 height Z-score.
Degrades VERY fast
Expensive compared to something like erda or infig.
FOXO4-DRI
FOXO4-DRI
View attachment 45172
FOXO4-DRI is a synthetic senolytic cell-penetrating peptide designed to selectively eliminate senescent cells (cells that stop dividing but secrete harmful inflammatory factors while healthy non-senescent cells are largely spared as it was designed to be selective)
How could it be used for height?
Growth plates naturally stop working (and height growth ends) because chondrocytes progressively enter senescence: they stop proliferating, secrete harmful inflammatory signals (the senescence-associated secretory phenotype, or SASP), and create a toxic microenvironment that further slows nearby healthy cells. This depletes the pool of resting-zone stem cells (epSSCs), shrinks the proliferative zone, reduces hypertrophic chondrocyte activity, and eventually leads to growth-plate thinning and fusion. Senescence is the main “programmed brake” on adult height.
FOXO4-DRI is designed to exploit a vulnerability unique to senescent cells: it disrupts the protective binding between FOXO4 and p53. In senescent chondrocytes (which rely heavily on this interaction to survive), this causes p53 to exit the nucleus, move to mitochondria, and trigger apoptosis (programmed cell death)
In Short
It would remove the accumulated senescent chondrocytes that are secreting SASP factors (IL-6, MMPs, etc.). Reduce inflammation and paracrine inhibition in the growth plate
Delay the overall “cell-counting” timer of senescence and postpone growth plate closure.
And allows epiphyseal skeletal stem cells and proliferative chondrocytes to expand, form longer columns, and maintain active endochondral ossification
However, I wouldnt personally take it.
AAS for height growth
Anavar:
(oxandrolone)
View attachment 45179
Mildest oral anabolic of the three. Temporarily boosts linear growth in some medical settings but advances bone age disproportionately. Lowest relative risk among the three for rapid closure, yet still causes net loss or no gain in adult height potential in normal teens.
Winstrol:
View attachment 45177
Animal data shows direct effects on growth plate chondrocytes
Halo:
(halotestin/fluoxymesterone)
View attachment 45178
Strongest/most potent androgen of the three (highly liver-toxic). Fastest bone maturation effect; FDA labels explicitly warn that androgens like this accelerate epiphyseal closure without compensatory linear growth in children. Highest risk of stunting height (if retarded)
TL;DR
Anavar increased height velocity but accelerated skeletal age more; some children lost predicted adult height (1.5–7.5 cm)
TL;DR
Winstrol affected proliferation of growth plate cells in adolescent rats (via estrogen receptor pathways). Shows direct impact on the growth plate but in a suppressed puberty model
TL;DR
Low-dose Halo increased growth velocity but required careful bone age monitoring. Final height exceeded predictions only in delayed cases
In conclusion
anavar has the most evidence for increased height velocity (despite me only showing one study for each).
however you have to be careful to not cause alot of bone maturation which isnt too hard. Best of luck
When you take any AAS even at a low dose the drug travels through your bloodstream and reaches the growth plates. There it binds directly to androgen receptors on the chondrocytes, the cartilage cells responsible for making new bone. These androgen receptors do not care if the dose is high or low; they simply respond to the presence of the molecule. Their job is to accelerate terminal differentiation, basically telling the chondrocytes to stop dividing and to mature faster into bone.
Therefore it is utter cope
for the help.
Tamoxifen
Tamoxifen:
View attachment 45173
selective estrogen receptor modulator (SERM), a drug that binds to estrogen receptors (mainly ERα and ERβ) and can act as either an estrogen blocker (antagonist) or estrogen mimic (agonist) depending on the tissue. It is FDA-approved primarily for treating and preventing estrogen receptor-positive breast cancer in adults, and it is also used off label for conditions like gynecomastia
How Tamoxifen Works
Tamoxifen competes directly with estradiol (E2) for binding to estrogen receptors in target cells
In growth-plate chondrocytes (cartilage cells responsible for bone lengthening), it can exert anti-estrogenic effects by inhibiting specific downstream signaling pathways triggered by E2, such as protein kinase C (PKC). This modulates chondrocyte differentiation and profileration
TL;DR
7 short pubertal boys (average age ~15) treated with tamoxifen (twice daily for 6 months–4 years; some also on GH). Tamoxifen significantly slowed skeletal maturation and increased predicted adult height by 4 inches (from ~5'6" to ~5'10") with no negative effects on sexual maturation or puberty progression
However authors called for larger prospective studies to confirm if this translates to actual final height gain
TL;DR
In vivo study in young male rats given clinically relevant doses for 4 weeks (followed by 14-week recovery). Tamoxifen caused persistent shorter tibia and reduced cortical bone size/strength, increased chondrocyte apoptosis, narrowed growth plates, and lowered serum IGF-1 levels
Socs2 inhibition
SOCS2:
(Suppressor of Cytokine Signaling 2)
View attachment 45174
Is a protein encoded by the SOCS2 gene in humans. It belongs to the SOCS family of intracellular proteins that act as negative feedback regulators of cytokine signaling, primarily through the JAK/STAT pathway
SOCS2 is a key negative regulator of growth hormone (GH) signaling. It binds to the phosphorylated GH receptor (GHR), promotes its ubiquitination and degradation (via the ECS ubiquitin ligase complex), and thereby dampens downstream STAT5 activation and IGF-1 production. This limits the anabolic and growth-promoting effects of GH/IGF-1
Which basically means SOCS2 is an inhibitor of GH Because SOCS2 inhibits GH signaling, reducing or blocking SOCS2 function removes this brake. This leads to enhanced GH receptor sensitivity, prolonged STAT5 signaling, higher local and systemic IGF-1, and increased linear bone growth. They are kinda like FGFR3 inhibitors.
•Significant linear growth enhancement
•Amplifies exogenous GH
•Targeted and reversible
•Metabolic risks from chronic GH/IGF-1 hyper-signaling: Potential insulin resistance,ect
IGF-1 is mitogenic; SOCS2 has complex roles in cancer (sometimes tumor-suppressive, sometimes pro-tumor in specific tissues)
•Potential organ enlargement
•Not too many ways to actually inhibit
TL;DR
mice grew 30–40% larger than wild-type, increased body weight, long-bone length, and proportional enlargement of most organs
TL;DR
Naturally occurring deletion of SOCS2 increased growth significantly however shortened lifespan in some mice
TL;DR
Mutation in SOCS2 linked to gigantism (increased height/weight) in human model
PTHrP analogues
PTHrP analogues:
View attachment 45171
Synthetic peptides that mimic parathyroid hormone-related protein (PTHrP), a key local regulator of the growth plate. The main clinically available ones are abaloparatide (Tymlos; a modified PTHrP(1-34) analogue) and teriparatide (Forteo; recombinant human PTH(1-34)). Both bind and activate the same receptor (PTH1R) that native PTHrP uses in chondrocytes, but they are given as daily subcutaneous injections.
In the epiphyseal growth plate, PTHrP is produced locally by resting-zone chondrocytes (including skeletal stem cells). It acts via PTH1R to Keep chondrocytes in the proliferative state, delay their maturation into hypertrophic cells and maintain the Ihh–PTHrP feedback loop that controls the pace of endochondral ossification
Intermittent (once-daily) dosing of PTHrP/PTH analogues mimics this natural signaling in a pulsed way that strongly stimulates bone formation meaning these compounds would:
•Expand the proliferative and hypertrophic zones
Increase chondrocyte columns and cartilage thickness
•Prolong active growth before senescence/closure
In short increasing height
Abalo and Teri Comparison:
Abalo pros:
•Designed to copy PTHrP’s natural growth-plate role more closely
•Potentially cleaner anabolic effect with less unwanted resorption or calcium spikes
•Rat data suggest stronger stimulation of cartilage thickness and site-specific bone lengthening
Abalo cons:
•Far less real-world pediatric data
osteosarcoma risk as seen in high dose rat studies
Teri pros:
•Decades more safety/efficacy data in humans
Proven to stimulate longitudinal growth in animal models
Teri cons:
•more resorption and higher hypercalcemia risk
Less selective
In conclusion abalo would be the better choice here however it has alot less research so, its down to preference.
SCO240
SCO240:
An oral small-molecule antagonist of somatostatin receptor type 5 (SSTR5). It is a first in class compound designed to stimulate endogenous GH secretion
from the pituitary gland
Somatostatin normally inhibits GH release by binding to SSTR5 on pituitary somatotroph cells. SCO-240 blocks this receptor selectively, removing the inhibition and allowing the body to release more of its own GH in a more physiological (pulsatile) pattern — without affecting other pituitary hormones (prolactin, TSH, ACTH, FSH, LH).
By boosting natural GH secretion, SCO-240 increases downstream IGF-1 production, which directly promotes chondrocyte proliferation and hypertrophy leading to increased growth velocity.
•Oral (convenience)
•Highly selective for GH
•Physiological GH release: mimics natural pulsatile pattern more closely than injected rhGH.
•Only phase 1 data in healthy adults; no published efficacy or height data in children with GHD or short stature yet.
•Basic GH excess risks (insulin resistance ect)
•Sourcing + Prices
•Limited data
TL;DR
Caused robust, dose-dependent GH secretion (comparable to therapeutic rhGH levels) with no effect on other pituitary hormones, insulin, or GLP-1.
Growth Plates
Resting Zone
This is the top layer of the growth plate, right near the end of the bone. The cells here are mostly stagnant and don’t divide much. They act like a stock of spare cartilage cells. Their job is to slowly supply new cells to the layers below when needed.
Proliferating Zone
This is the busy factory zone. The cartilage cells divide quickly and stack up in neat columns, like coins piled on top of each other. Every time they multiply, they add a bit more length to the bone. This is where most of the actual growth in height happens. It’s the most active part of the growth plate.
Hypertrophic Zone
In this zone, the cells stop dividing and start getting much bigger. As they grow larger, they help push the bone longer. Then they prepare the area by making the cartilage matrix harder. Eventually the cells die off, and the hardened cartilage gets replaced by real bone. This is the last step before the cartilage turns into solid bone.
____________________________________________________________________
Conclusion:
Leave a rep if you enjoyed
Test tren?Heightmaxxing 202
By: Fent
____________________________________________________________________
Table of Contents:
FGFR3 inhibitors
CXXC5 inhibitors
SAG's
Vosoritide
Foxo4-dri
AAS for height growth
-Winstrol
-Anavar
-Halotestin
Tamoxifen
Socs2 inhibition
PTHrP analogues
SCO240
____________________________________________________________________
FGFR3 Inhibitors
What are FGFR3 Inhibitors
View attachment 45160
FGFR3 inhibitors are drugs that block the Fibroblast Growth Factor Receptor 3 protein FGFR3 normally acts like a brake on bone growth in the growth plates (the cartilage areas at the ends of long bones that allow you to get taller during childhood and adolescence). By inhibiting FGFR3, these drugs reduce that braking effect, allowing chondrocytes to proliferate and mature more freely. This leads to increased linear bone growth and greater height velocity especially in conditions like achondroplasia where the receptor is overactive due to a genetic mutation.
Types of FGFR3 inhibitors
•Infigratinib
•Erdafitinib
•Tyra-300 (dabogratinib)
•Loxo435
Infigratinib
Orally bioavailable, FGFR1-3 selective ATP-competitive TKI. It binds the ATP pocket of FGFR1, FGFR2, and FGFR3 (with much weaker activity on FGFR4 and VEGFR2). This dual inhibition hits both MAPK (hypertrophy) and STAT1 (proliferation) pathways downstream of FGFR3.
TL;DR
Once daily oral infigratinib (0.25 mg/kg) gave +1.74 cm/year (LS mean) or +2.10 cm/year extra annualized height velocity (AHV) vs placebo at 52 weeks. Absolute AHV reached 5.96 cm/year (highest reported in any ACH randomized trial). First drug to show statistically significant improvement in upper-to-lower body proportionality. Well tolerated; no FGFR1/2-related AEs or serious treatment-related events.
TL;DR
In ACH kids, highest dose produced +2.50 cm/year change in AHV from baseline at 18 months, +0.54 height Z-score, and improved proportionality (upper:lower ratio –0.12). Sustained effect, good safety.
TL;DR
Low dose infigratinib increased femur length, growth plate proliferative zone, and corrected disproportionate growth in Fgfr3 mutant mice.
Erdafitinib
Oral pan-FGFR (FGFR1-4) TKI. First FDA-approved pan-FGFR inhibitor (2019, for FGFR-altered urothelial cancer). Most potent against FGFR1, followed by FGFR3 > FGFR4 > FGFR2. Less selective than the others, so more off-target potential. (Not the best)
TL;DR
Pre-pubescent child with FGFR1-mutated glioma on erdafitinib showed rapid long-bone overgrowth, kyphoscoliosis, and spinal deformities within months
TL;DR
Cancer patients on erdafitinib had growth-factor and sex steroid independent acceleration of linear growth via FGFR3 inhibition. Proves the mechanism works for height but also carries severe risk.
Tyra-300
Oral, highly isoform-selective FGFR3 TKI (first-in-class FGFR3-selective). Designed with TYRA’s SNÅP platform to potently hit FGFR3 while sparing FGFR1/2/4 to minimize off-target toxicity. Once daily small molecule.
TL;DR
n wild-type mice + two FGFR3-driven models (ACH and hypochondroplasia), TYRA-300 significantly increased long-bone length (femur +3.7–5%, tibia +3.75–6%, etc.), nasoanal length, foramen magnum size, and improved skeletal proportionality and bone quality. First clear data showing FGFR3-selective inhibition works even in normal genetics. (Huge)
Loxo435
Oral, highly isoform-selective FGFR3 inhibitor (potent small-molecule TKI). Engineered by LOXO Oncology / Eli Lilly (goat) to maximize FGFR3 potency while minimizing off-target effects on other FGFRs and kinases for better safety.
There isnt too many studies i thought were worth showing however it looks promising alongside tyra-300 as a selective FGFR3 Inhibitor.
Biggest Con With Each Inhibitor:
Infigratinib:
• hyperphosphatemia
Erdafitinib:
•Rapid overgrowth (if retarded), Slipped capital femoral epiphysis and growth plate changes + premature fusion
Tyra-300:
•Unknown, as there is not enough studies+ pricing
Loxo435:
•same with tyra
CXXC5 Inhibitors
CXXC5
View attachment 45161
Acts as a negative regulator of human height by accelerating growth plate senescence and limiting longitudinal bone growth. It functions as a feedback inhibitor of the Wnt/β-catenin signaling pathway, which is paramount for maintaining chondrocyte proliferation and delaying senescence in the epiphyseal growth plates.
Induced by Wnt signaling itself and by estrogen (via estrogen receptor alpha), CXXC5 interacts with Dishevelled (DVL) to suppress β-catenin activity, thereby reducing chondrocyte proliferation, hypertrophy, and overall bone elongation.
In mouse models, CXXC5 knockout results in delayed growth plate senescence, increased tibial length, expanded proliferative and hypertrophic zones, and higher bone mass due to enhanced Wnt signaling. Pharmacological disruption of the CXXC5–DVL interaction has been shown to promote bone growth in preclinical studies, suggesting potential therapeutic applications for short stature caused by premature growth plate closure
The only CXXC5 inhib i think worth talking about is KY19382
KY19382
View attachment 45180
A small-molecule dual inhibitor that blocks CXXC5 (a protein that speeds up growth plate senescence/aging, which stops you from growing taller) from binding to dishevelled, while also inhibiting GSK3β.
This strongly activates the Wnt/β-catenin pathway inside growth-plate cartilage cells, delaying senescence, boosting chondrocyte proliferation, and keeping the growth plates active longer so bones can keep lengthening
Administration:
• Transdermally
- (not preferred imo)
• Subcutaneous Injection
“A functionally improved indirubin derivative, KY19382, elongated tibial length through delayed senescence and further activation of the growth plate in adolescent mice.”
Directly from the abstract; the full paper also states:
“Our results showed that KY19382 effectively increased the longitudinal growth of tibiae by delaying growth plate senescence through the accompanying promotion of chondrocyte proliferation and differentiation.”
Only con is theres no data in long term use
SAG21k and Purmorphamine
SAG21k and Purmorphamine
Small drug like molecules that directly switch on the Smoothened (SMO) receptor in the Hedgehog (Hh/Ihh/Shh) signaling pathway.
In the growth plates of growing bones, they completely bypass the normal control step where the Ihh signal inhibits Patched. This instantly activates Gli transcription factors.
The Result:
more epiphyseal skeletal stem cells (epSSCs) multiply in the resting zone, cartilage cells (chondrocytes) grow faster and form bigger clusters, a special environment is created that blocks Wnt signals to keep stem cells active, and the process of turning cartilage into bone speeds up.
Overall, this makes the growth plates thicker and leads to greater longitudinal bone lengthening
TL;DR
Systemic SAG21k (5 mg/kg/day IP for 7 days) in a mouse bone-defect model strongly enhanced early chondrogenesis via SHH pathway activation, creating more cartilage template that later ossified into greater bone
•Most likely cancer causing due to hedgehog pathway overactivation
•Price
•Sourcing
•You need a special delivery method for it
However, if you can source, afford and use it strategically so you dont get cancer, one of the greatest heightmaxx compounds
Vosoritide + CNP
What is CNP
CNP is a natural peptide hormone produced locally right inside your growth plates by chondrocytes (the cartilage cells that turn into bone CNP’s job is promoting endochondral bone growth (the exact process that makes your long bones femurs, tibias, etc longer during childhood/adolescence.)
CNP binds to its receptor NPR-B on chondrocytes, this ramps up intracellular cGMP (a signaling molecule).
cGMP then inhibits the MAPK/ERK pathway
Chondrocytes proliferate more, mature faster (hypertrophy), and produce more bone matrix and longer bones and increased height velocity.
Vosoritide
View attachment 45175
Vosoritide is a lab-made, longer lasting analog of CNP (39-amino-acid version engineered to resist quick breakdown). It’s given as a daily subcutaneous injection and is the first (and currently only) approved drug that directly harnesses this pathway for ACH. Vosoritide mimics CNP, binds NPR-B, raises cGMP, and counteracts FGFR3 signaling downstream (without touching the FGFR3 receptor itself meaning it is indirect).
TLDR 121 ACH kids (5–18 years). Vosoritide 15 µg/kg daily --> +1.57 cm/year extra AGV vs placebo (5.39 vs 3.81 cm/year at 52 weeks). Also +0.28 height Z-score.
Degrades VERY fast
Expensive compared to something like erda or infig.
FOXO4-DRI
FOXO4-DRI
View attachment 45172
FOXO4-DRI is a synthetic senolytic cell-penetrating peptide designed to selectively eliminate senescent cells (cells that stop dividing but secrete harmful inflammatory factors while healthy non-senescent cells are largely spared as it was designed to be selective)
How could it be used for height?
Growth plates naturally stop working (and height growth ends) because chondrocytes progressively enter senescence: they stop proliferating, secrete harmful inflammatory signals (the senescence-associated secretory phenotype, or SASP), and create a toxic microenvironment that further slows nearby healthy cells. This depletes the pool of resting-zone stem cells (epSSCs), shrinks the proliferative zone, reduces hypertrophic chondrocyte activity, and eventually leads to growth-plate thinning and fusion. Senescence is the main “programmed brake” on adult height.
FOXO4-DRI is designed to exploit a vulnerability unique to senescent cells: it disrupts the protective binding between FOXO4 and p53. In senescent chondrocytes (which rely heavily on this interaction to survive), this causes p53 to exit the nucleus, move to mitochondria, and trigger apoptosis (programmed cell death)
In Short
It would remove the accumulated senescent chondrocytes that are secreting SASP factors (IL-6, MMPs, etc.). Reduce inflammation and paracrine inhibition in the growth plate
Delay the overall “cell-counting” timer of senescence and postpone growth plate closure.
And allows epiphyseal skeletal stem cells and proliferative chondrocytes to expand, form longer columns, and maintain active endochondral ossification
However, I wouldnt personally take it.
AAS for height growth
Anavar:
(oxandrolone)
View attachment 45179
Mildest oral anabolic of the three. Temporarily boosts linear growth in some medical settings but advances bone age disproportionately. Lowest relative risk among the three for rapid closure, yet still causes net loss or no gain in adult height potential in normal teens.
Winstrol:
View attachment 45177
Animal data shows direct effects on growth plate chondrocytes
Halo:
(halotestin/fluoxymesterone)
View attachment 45178
Strongest/most potent androgen of the three (highly liver-toxic). Fastest bone maturation effect; FDA labels explicitly warn that androgens like this accelerate epiphyseal closure without compensatory linear growth in children. Highest risk of stunting height (if retarded)
TL;DR
Anavar increased height velocity but accelerated skeletal age more; some children lost predicted adult height (1.5–7.5 cm)
TL;DR
Winstrol affected proliferation of growth plate cells in adolescent rats (via estrogen receptor pathways). Shows direct impact on the growth plate but in a suppressed puberty model
TL;DR
Low-dose Halo increased growth velocity but required careful bone age monitoring. Final height exceeded predictions only in delayed cases
In conclusion
anavar has the most evidence for increased height velocity (despite me only showing one study for each).
however you have to be careful to not cause alot of bone maturation which isnt too hard. Best of luck
When you take any AAS even at a low dose the drug travels through your bloodstream and reaches the growth plates. There it binds directly to androgen receptors on the chondrocytes, the cartilage cells responsible for making new bone. These androgen receptors do not care if the dose is high or low; they simply respond to the presence of the molecule. Their job is to accelerate terminal differentiation, basically telling the chondrocytes to stop dividing and to mature faster into bone.
Therefore it is utter cope
for the help.
Tamoxifen
Tamoxifen:
View attachment 45173
selective estrogen receptor modulator (SERM), a drug that binds to estrogen receptors (mainly ERα and ERβ) and can act as either an estrogen blocker (antagonist) or estrogen mimic (agonist) depending on the tissue. It is FDA-approved primarily for treating and preventing estrogen receptor-positive breast cancer in adults, and it is also used off label for conditions like gynecomastia
How Tamoxifen Works
Tamoxifen competes directly with estradiol (E2) for binding to estrogen receptors in target cells
In growth-plate chondrocytes (cartilage cells responsible for bone lengthening), it can exert anti-estrogenic effects by inhibiting specific downstream signaling pathways triggered by E2, such as protein kinase C (PKC). This modulates chondrocyte differentiation and profileration
TL;DR
7 short pubertal boys (average age ~15) treated with tamoxifen (twice daily for 6 months–4 years; some also on GH). Tamoxifen significantly slowed skeletal maturation and increased predicted adult height by 4 inches (from ~5'6" to ~5'10") with no negative effects on sexual maturation or puberty progression
However authors called for larger prospective studies to confirm if this translates to actual final height gain
TL;DR
In vivo study in young male rats given clinically relevant doses for 4 weeks (followed by 14-week recovery). Tamoxifen caused persistent shorter tibia and reduced cortical bone size/strength, increased chondrocyte apoptosis, narrowed growth plates, and lowered serum IGF-1 levels
Socs2 inhibition
SOCS2:
(Suppressor of Cytokine Signaling 2)
View attachment 45174
Is a protein encoded by the SOCS2 gene in humans. It belongs to the SOCS family of intracellular proteins that act as negative feedback regulators of cytokine signaling, primarily through the JAK/STAT pathway
SOCS2 is a key negative regulator of growth hormone (GH) signaling. It binds to the phosphorylated GH receptor (GHR), promotes its ubiquitination and degradation (via the ECS ubiquitin ligase complex), and thereby dampens downstream STAT5 activation and IGF-1 production. This limits the anabolic and growth-promoting effects of GH/IGF-1
Which basically means SOCS2 is an inhibitor of GH Because SOCS2 inhibits GH signaling, reducing or blocking SOCS2 function removes this brake. This leads to enhanced GH receptor sensitivity, prolonged STAT5 signaling, higher local and systemic IGF-1, and increased linear bone growth. They are kinda like FGFR3 inhibitors.
•Significant linear growth enhancement
•Amplifies exogenous GH
•Targeted and reversible
•Metabolic risks from chronic GH/IGF-1 hyper-signaling: Potential insulin resistance,ect
IGF-1 is mitogenic; SOCS2 has complex roles in cancer (sometimes tumor-suppressive, sometimes pro-tumor in specific tissues)
•Potential organ enlargement
•Not too many ways to actually inhibit
TL;DR
mice grew 30–40% larger than wild-type, increased body weight, long-bone length, and proportional enlargement of most organs
TL;DR
Naturally occurring deletion of SOCS2 increased growth significantly however shortened lifespan in some mice
TL;DR
Mutation in SOCS2 linked to gigantism (increased height/weight) in human model
PTHrP analogues
PTHrP analogues:
View attachment 45171
Synthetic peptides that mimic parathyroid hormone-related protein (PTHrP), a key local regulator of the growth plate. The main clinically available ones are abaloparatide (Tymlos; a modified PTHrP(1-34) analogue) and teriparatide (Forteo; recombinant human PTH(1-34)). Both bind and activate the same receptor (PTH1R) that native PTHrP uses in chondrocytes, but they are given as daily subcutaneous injections.
In the epiphyseal growth plate, PTHrP is produced locally by resting-zone chondrocytes (including skeletal stem cells). It acts via PTH1R to Keep chondrocytes in the proliferative state, delay their maturation into hypertrophic cells and maintain the Ihh–PTHrP feedback loop that controls the pace of endochondral ossification
Intermittent (once-daily) dosing of PTHrP/PTH analogues mimics this natural signaling in a pulsed way that strongly stimulates bone formation meaning these compounds would:
•Expand the proliferative and hypertrophic zones
Increase chondrocyte columns and cartilage thickness
•Prolong active growth before senescence/closure
In short increasing height
Abalo and Teri Comparison:
Abalo pros:
•Designed to copy PTHrP’s natural growth-plate role more closely
•Potentially cleaner anabolic effect with less unwanted resorption or calcium spikes
•Rat data suggest stronger stimulation of cartilage thickness and site-specific bone lengthening
Abalo cons:
•Far less real-world pediatric data
osteosarcoma risk as seen in high dose rat studies
Teri pros:
•Decades more safety/efficacy data in humans
Proven to stimulate longitudinal growth in animal models
Teri cons:
•more resorption and higher hypercalcemia risk
Less selective
In conclusion abalo would be the better choice here however it has alot less research so, its down to preference.
SCO240
SCO240:
An oral small-molecule antagonist of somatostatin receptor type 5 (SSTR5). It is a first in class compound designed to stimulate endogenous GH secretion
from the pituitary gland
Somatostatin normally inhibits GH release by binding to SSTR5 on pituitary somatotroph cells. SCO-240 blocks this receptor selectively, removing the inhibition and allowing the body to release more of its own GH in a more physiological (pulsatile) pattern — without affecting other pituitary hormones (prolactin, TSH, ACTH, FSH, LH).
By boosting natural GH secretion, SCO-240 increases downstream IGF-1 production, which directly promotes chondrocyte proliferation and hypertrophy leading to increased growth velocity.
•Oral (convenience)
•Highly selective for GH
•Physiological GH release: mimics natural pulsatile pattern more closely than injected rhGH.
•Only phase 1 data in healthy adults; no published efficacy or height data in children with GHD or short stature yet.
•Basic GH excess risks (insulin resistance ect)
•Sourcing + Prices
•Limited data
TL;DR
Caused robust, dose-dependent GH secretion (comparable to therapeutic rhGH levels) with no effect on other pituitary hormones, insulin, or GLP-1.
Growth Plates
Resting Zone
This is the top layer of the growth plate, right near the end of the bone. The cells here are mostly stagnant and don’t divide much. They act like a stock of spare cartilage cells. Their job is to slowly supply new cells to the layers below when needed.
Proliferating Zone
This is the busy factory zone. The cartilage cells divide quickly and stack up in neat columns, like coins piled on top of each other. Every time they multiply, they add a bit more length to the bone. This is where most of the actual growth in height happens. It’s the most active part of the growth plate.
Hypertrophic Zone
In this zone, the cells stop dividing and start getting much bigger. As they grow larger, they help push the bone longer. Then they prepare the area by making the cartilage matrix harder. Eventually the cells die off, and the hardened cartilage gets replaced by real bone. This is the last step before the cartilage turns into solid bone.
____________________________________________________________________
Conclusion:
Leave a rep if you enjoyed
Sorb
Iron
- Joined
- Apr 10, 2026
- Posts
- 19
- Reputation
- 6
Why no test base and an ai? erectile dysfunction and permanent test suppression are callingHeightmaxxing 202
By: Fent
____________________________________________________________________
Table of Contents:
FGFR3 inhibitors
CXXC5 inhibitors
SAG's
Vosoritide
Foxo4-dri
AAS for height growth
-Winstrol
-Anavar
-Halotestin
Tamoxifen
Socs2 inhibition
PTHrP analogues
SCO240
____________________________________________________________________
FGFR3 Inhibitors
What are FGFR3 Inhibitors
View attachment 45160
FGFR3 inhibitors are drugs that block the Fibroblast Growth Factor Receptor 3 protein FGFR3 normally acts like a brake on bone growth in the growth plates (the cartilage areas at the ends of long bones that allow you to get taller during childhood and adolescence). By inhibiting FGFR3, these drugs reduce that braking effect, allowing chondrocytes to proliferate and mature more freely. This leads to increased linear bone growth and greater height velocity especially in conditions like achondroplasia where the receptor is overactive due to a genetic mutation.
Types of FGFR3 inhibitors
•Infigratinib
•Erdafitinib
•Tyra-300 (dabogratinib)
•Loxo435
Infigratinib
Orally bioavailable, FGFR1-3 selective ATP-competitive TKI. It binds the ATP pocket of FGFR1, FGFR2, and FGFR3 (with much weaker activity on FGFR4 and VEGFR2). This dual inhibition hits both MAPK (hypertrophy) and STAT1 (proliferation) pathways downstream of FGFR3.
TL;DR
Once daily oral infigratinib (0.25 mg/kg) gave +1.74 cm/year (LS mean) or +2.10 cm/year extra annualized height velocity (AHV) vs placebo at 52 weeks. Absolute AHV reached 5.96 cm/year (highest reported in any ACH randomized trial). First drug to show statistically significant improvement in upper-to-lower body proportionality. Well tolerated; no FGFR1/2-related AEs or serious treatment-related events.
TL;DR
In ACH kids, highest dose produced +2.50 cm/year change in AHV from baseline at 18 months, +0.54 height Z-score, and improved proportionality (upper:lower ratio –0.12). Sustained effect, good safety.
TL;DR
Low dose infigratinib increased femur length, growth plate proliferative zone, and corrected disproportionate growth in Fgfr3 mutant mice.
Erdafitinib
Oral pan-FGFR (FGFR1-4) TKI. First FDA-approved pan-FGFR inhibitor (2019, for FGFR-altered urothelial cancer). Most potent against FGFR1, followed by FGFR3 > FGFR4 > FGFR2. Less selective than the others, so more off-target potential. (Not the best)
TL;DR
Pre-pubescent child with FGFR1-mutated glioma on erdafitinib showed rapid long-bone overgrowth, kyphoscoliosis, and spinal deformities within months
TL;DR
Cancer patients on erdafitinib had growth-factor and sex steroid independent acceleration of linear growth via FGFR3 inhibition. Proves the mechanism works for height but also carries severe risk.
Tyra-300
Oral, highly isoform-selective FGFR3 TKI (first-in-class FGFR3-selective). Designed with TYRA’s SNÅP platform to potently hit FGFR3 while sparing FGFR1/2/4 to minimize off-target toxicity. Once daily small molecule.
TL;DR
n wild-type mice + two FGFR3-driven models (ACH and hypochondroplasia), TYRA-300 significantly increased long-bone length (femur +3.7–5%, tibia +3.75–6%, etc.), nasoanal length, foramen magnum size, and improved skeletal proportionality and bone quality. First clear data showing FGFR3-selective inhibition works even in normal genetics. (Huge)
Loxo435
Oral, highly isoform-selective FGFR3 inhibitor (potent small-molecule TKI). Engineered by LOXO Oncology / Eli Lilly (goat) to maximize FGFR3 potency while minimizing off-target effects on other FGFRs and kinases for better safety.
There isnt too many studies i thought were worth showing however it looks promising alongside tyra-300 as a selective FGFR3 Inhibitor.
Biggest Con With Each Inhibitor:
Infigratinib:
• hyperphosphatemia
Erdafitinib:
•Rapid overgrowth (if retarded), Slipped capital femoral epiphysis and growth plate changes + premature fusion
Tyra-300:
•Unknown, as there is not enough studies+ pricing
Loxo435:
•same with tyra
CXXC5 Inhibitors
CXXC5
View attachment 45161
Acts as a negative regulator of human height by accelerating growth plate senescence and limiting longitudinal bone growth. It functions as a feedback inhibitor of the Wnt/β-catenin signaling pathway, which is paramount for maintaining chondrocyte proliferation and delaying senescence in the epiphyseal growth plates.
Induced by Wnt signaling itself and by estrogen (via estrogen receptor alpha), CXXC5 interacts with Dishevelled (DVL) to suppress β-catenin activity, thereby reducing chondrocyte proliferation, hypertrophy, and overall bone elongation.
In mouse models, CXXC5 knockout results in delayed growth plate senescence, increased tibial length, expanded proliferative and hypertrophic zones, and higher bone mass due to enhanced Wnt signaling. Pharmacological disruption of the CXXC5–DVL interaction has been shown to promote bone growth in preclinical studies, suggesting potential therapeutic applications for short stature caused by premature growth plate closure
The only CXXC5 inhib i think worth talking about is KY19382
KY19382
View attachment 45180
A small-molecule dual inhibitor that blocks CXXC5 (a protein that speeds up growth plate senescence/aging, which stops you from growing taller) from binding to dishevelled, while also inhibiting GSK3β.
This strongly activates the Wnt/β-catenin pathway inside growth-plate cartilage cells, delaying senescence, boosting chondrocyte proliferation, and keeping the growth plates active longer so bones can keep lengthening
Administration:
• Transdermally
- (not preferred imo)
• Subcutaneous Injection
“A functionally improved indirubin derivative, KY19382, elongated tibial length through delayed senescence and further activation of the growth plate in adolescent mice.”
Directly from the abstract; the full paper also states:
“Our results showed that KY19382 effectively increased the longitudinal growth of tibiae by delaying growth plate senescence through the accompanying promotion of chondrocyte proliferation and differentiation.”
Only con is theres no data in long term use
SAG21k and Purmorphamine
SAG21k and Purmorphamine
Small drug like molecules that directly switch on the Smoothened (SMO) receptor in the Hedgehog (Hh/Ihh/Shh) signaling pathway.
In the growth plates of growing bones, they completely bypass the normal control step where the Ihh signal inhibits Patched. This instantly activates Gli transcription factors.
The Result:
more epiphyseal skeletal stem cells (epSSCs) multiply in the resting zone, cartilage cells (chondrocytes) grow faster and form bigger clusters, a special environment is created that blocks Wnt signals to keep stem cells active, and the process of turning cartilage into bone speeds up.
Overall, this makes the growth plates thicker and leads to greater longitudinal bone lengthening
TL;DR
Systemic SAG21k (5 mg/kg/day IP for 7 days) in a mouse bone-defect model strongly enhanced early chondrogenesis via SHH pathway activation, creating more cartilage template that later ossified into greater bone
•Most likely cancer causing due to hedgehog pathway overactivation
•Price
•Sourcing
•You need a special delivery method for it
However, if you can source, afford and use it strategically so you dont get cancer, one of the greatest heightmaxx compounds
Vosoritide + CNP
What is CNP
CNP is a natural peptide hormone produced locally right inside your growth plates by chondrocytes (the cartilage cells that turn into bone CNP’s job is promoting endochondral bone growth (the exact process that makes your long bones femurs, tibias, etc longer during childhood/adolescence.)
CNP binds to its receptor NPR-B on chondrocytes, this ramps up intracellular cGMP (a signaling molecule).
cGMP then inhibits the MAPK/ERK pathway
Chondrocytes proliferate more, mature faster (hypertrophy), and produce more bone matrix and longer bones and increased height velocity.
Vosoritide
View attachment 45175
Vosoritide is a lab-made, longer lasting analog of CNP (39-amino-acid version engineered to resist quick breakdown). It’s given as a daily subcutaneous injection and is the first (and currently only) approved drug that directly harnesses this pathway for ACH. Vosoritide mimics CNP, binds NPR-B, raises cGMP, and counteracts FGFR3 signaling downstream (without touching the FGFR3 receptor itself meaning it is indirect).
TLDR 121 ACH kids (5–18 years). Vosoritide 15 µg/kg daily --> +1.57 cm/year extra AGV vs placebo (5.39 vs 3.81 cm/year at 52 weeks). Also +0.28 height Z-score.
Degrades VERY fast
Expensive compared to something like erda or infig.
FOXO4-DRI
FOXO4-DRI
View attachment 45172
FOXO4-DRI is a synthetic senolytic cell-penetrating peptide designed to selectively eliminate senescent cells (cells that stop dividing but secrete harmful inflammatory factors while healthy non-senescent cells are largely spared as it was designed to be selective)
How could it be used for height?
Growth plates naturally stop working (and height growth ends) because chondrocytes progressively enter senescence: they stop proliferating, secrete harmful inflammatory signals (the senescence-associated secretory phenotype, or SASP), and create a toxic microenvironment that further slows nearby healthy cells. This depletes the pool of resting-zone stem cells (epSSCs), shrinks the proliferative zone, reduces hypertrophic chondrocyte activity, and eventually leads to growth-plate thinning and fusion. Senescence is the main “programmed brake” on adult height.
FOXO4-DRI is designed to exploit a vulnerability unique to senescent cells: it disrupts the protective binding between FOXO4 and p53. In senescent chondrocytes (which rely heavily on this interaction to survive), this causes p53 to exit the nucleus, move to mitochondria, and trigger apoptosis (programmed cell death)
In Short
It would remove the accumulated senescent chondrocytes that are secreting SASP factors (IL-6, MMPs, etc.). Reduce inflammation and paracrine inhibition in the growth plate
Delay the overall “cell-counting” timer of senescence and postpone growth plate closure.
And allows epiphyseal skeletal stem cells and proliferative chondrocytes to expand, form longer columns, and maintain active endochondral ossification
However, I wouldnt personally take it.
AAS for height growth
Anavar:
(oxandrolone)
View attachment 45179
Mildest oral anabolic of the three. Temporarily boosts linear growth in some medical settings but advances bone age disproportionately. Lowest relative risk among the three for rapid closure, yet still causes net loss or no gain in adult height potential in normal teens.
Winstrol:
View attachment 45177
Animal data shows direct effects on growth plate chondrocytes
Halo:
(halotestin/fluoxymesterone)
View attachment 45178
Strongest/most potent androgen of the three (highly liver-toxic). Fastest bone maturation effect; FDA labels explicitly warn that androgens like this accelerate epiphyseal closure without compensatory linear growth in children. Highest risk of stunting height (if retarded)
TL;DR
Anavar increased height velocity but accelerated skeletal age more; some children lost predicted adult height (1.5–7.5 cm)
TL;DR
Winstrol affected proliferation of growth plate cells in adolescent rats (via estrogen receptor pathways). Shows direct impact on the growth plate but in a suppressed puberty model
TL;DR
Low-dose Halo increased growth velocity but required careful bone age monitoring. Final height exceeded predictions only in delayed cases
In conclusion
anavar has the most evidence for increased height velocity (despite me only showing one study for each).
however you have to be careful to not cause alot of bone maturation which isnt too hard. Best of luck
When you take any AAS even at a low dose the drug travels through your bloodstream and reaches the growth plates. There it binds directly to androgen receptors on the chondrocytes, the cartilage cells responsible for making new bone. These androgen receptors do not care if the dose is high or low; they simply respond to the presence of the molecule. Their job is to accelerate terminal differentiation, basically telling the chondrocytes to stop dividing and to mature faster into bone.
Therefore it is utter cope
for the help.
Tamoxifen
Tamoxifen:
View attachment 45173
selective estrogen receptor modulator (SERM), a drug that binds to estrogen receptors (mainly ERα and ERβ) and can act as either an estrogen blocker (antagonist) or estrogen mimic (agonist) depending on the tissue. It is FDA-approved primarily for treating and preventing estrogen receptor-positive breast cancer in adults, and it is also used off label for conditions like gynecomastia
How Tamoxifen Works
Tamoxifen competes directly with estradiol (E2) for binding to estrogen receptors in target cells
In growth-plate chondrocytes (cartilage cells responsible for bone lengthening), it can exert anti-estrogenic effects by inhibiting specific downstream signaling pathways triggered by E2, such as protein kinase C (PKC). This modulates chondrocyte differentiation and profileration
TL;DR
7 short pubertal boys (average age ~15) treated with tamoxifen (twice daily for 6 months–4 years; some also on GH). Tamoxifen significantly slowed skeletal maturation and increased predicted adult height by 4 inches (from ~5'6" to ~5'10") with no negative effects on sexual maturation or puberty progression
However authors called for larger prospective studies to confirm if this translates to actual final height gain
TL;DR
In vivo study in young male rats given clinically relevant doses for 4 weeks (followed by 14-week recovery). Tamoxifen caused persistent shorter tibia and reduced cortical bone size/strength, increased chondrocyte apoptosis, narrowed growth plates, and lowered serum IGF-1 levels
Socs2 inhibition
SOCS2:
(Suppressor of Cytokine Signaling 2)
View attachment 45174
Is a protein encoded by the SOCS2 gene in humans. It belongs to the SOCS family of intracellular proteins that act as negative feedback regulators of cytokine signaling, primarily through the JAK/STAT pathway
SOCS2 is a key negative regulator of growth hormone (GH) signaling. It binds to the phosphorylated GH receptor (GHR), promotes its ubiquitination and degradation (via the ECS ubiquitin ligase complex), and thereby dampens downstream STAT5 activation and IGF-1 production. This limits the anabolic and growth-promoting effects of GH/IGF-1
Which basically means SOCS2 is an inhibitor of GH Because SOCS2 inhibits GH signaling, reducing or blocking SOCS2 function removes this brake. This leads to enhanced GH receptor sensitivity, prolonged STAT5 signaling, higher local and systemic IGF-1, and increased linear bone growth. They are kinda like FGFR3 inhibitors.
•Significant linear growth enhancement
•Amplifies exogenous GH
•Targeted and reversible
•Metabolic risks from chronic GH/IGF-1 hyper-signaling: Potential insulin resistance,ect
IGF-1 is mitogenic; SOCS2 has complex roles in cancer (sometimes tumor-suppressive, sometimes pro-tumor in specific tissues)
•Potential organ enlargement
•Not too many ways to actually inhibit
TL;DR
mice grew 30–40% larger than wild-type, increased body weight, long-bone length, and proportional enlargement of most organs
TL;DR
Naturally occurring deletion of SOCS2 increased growth significantly however shortened lifespan in some mice
TL;DR
Mutation in SOCS2 linked to gigantism (increased height/weight) in human model
PTHrP analogues
PTHrP analogues:
View attachment 45171
Synthetic peptides that mimic parathyroid hormone-related protein (PTHrP), a key local regulator of the growth plate. The main clinically available ones are abaloparatide (Tymlos; a modified PTHrP(1-34) analogue) and teriparatide (Forteo; recombinant human PTH(1-34)). Both bind and activate the same receptor (PTH1R) that native PTHrP uses in chondrocytes, but they are given as daily subcutaneous injections.
In the epiphyseal growth plate, PTHrP is produced locally by resting-zone chondrocytes (including skeletal stem cells). It acts via PTH1R to Keep chondrocytes in the proliferative state, delay their maturation into hypertrophic cells and maintain the Ihh–PTHrP feedback loop that controls the pace of endochondral ossification
Intermittent (once-daily) dosing of PTHrP/PTH analogues mimics this natural signaling in a pulsed way that strongly stimulates bone formation meaning these compounds would:
•Expand the proliferative and hypertrophic zones
Increase chondrocyte columns and cartilage thickness
•Prolong active growth before senescence/closure
In short increasing height
Abalo and Teri Comparison:
Abalo pros:
•Designed to copy PTHrP’s natural growth-plate role more closely
•Potentially cleaner anabolic effect with less unwanted resorption or calcium spikes
•Rat data suggest stronger stimulation of cartilage thickness and site-specific bone lengthening
Abalo cons:
•Far less real-world pediatric data
osteosarcoma risk as seen in high dose rat studies
Teri pros:
•Decades more safety/efficacy data in humans
Proven to stimulate longitudinal growth in animal models
Teri cons:
•more resorption and higher hypercalcemia risk
Less selective
In conclusion abalo would be the better choice here however it has alot less research so, its down to preference.
SCO240
SCO240:
An oral small-molecule antagonist of somatostatin receptor type 5 (SSTR5). It is a first in class compound designed to stimulate endogenous GH secretion
from the pituitary gland
Somatostatin normally inhibits GH release by binding to SSTR5 on pituitary somatotroph cells. SCO-240 blocks this receptor selectively, removing the inhibition and allowing the body to release more of its own GH in a more physiological (pulsatile) pattern — without affecting other pituitary hormones (prolactin, TSH, ACTH, FSH, LH).
By boosting natural GH secretion, SCO-240 increases downstream IGF-1 production, which directly promotes chondrocyte proliferation and hypertrophy leading to increased growth velocity.
•Oral (convenience)
•Highly selective for GH
•Physiological GH release: mimics natural pulsatile pattern more closely than injected rhGH.
•Only phase 1 data in healthy adults; no published efficacy or height data in children with GHD or short stature yet.
•Basic GH excess risks (insulin resistance ect)
•Sourcing + Prices
•Limited data
TL;DR
Caused robust, dose-dependent GH secretion (comparable to therapeutic rhGH levels) with no effect on other pituitary hormones, insulin, or GLP-1.
Growth Plates
Resting Zone
This is the top layer of the growth plate, right near the end of the bone. The cells here are mostly stagnant and don’t divide much. They act like a stock of spare cartilage cells. Their job is to slowly supply new cells to the layers below when needed.
Proliferating Zone
This is the busy factory zone. The cartilage cells divide quickly and stack up in neat columns, like coins piled on top of each other. Every time they multiply, they add a bit more length to the bone. This is where most of the actual growth in height happens. It’s the most active part of the growth plate.
Hypertrophic Zone
In this zone, the cells stop dividing and start getting much bigger. As they grow larger, they help push the bone longer. Then they prepare the area by making the cartilage matrix harder. Eventually the cells die off, and the hardened cartilage gets replaced by real bone. This is the last step before the cartilage turns into solid bone.
____________________________________________________________________
Conclusion:
Leave a rep if you enjoyed
fent
Serial Heightmaxxer
- Joined
- Jan 19, 2026
- Posts
- 1,622
- Reputation
- 5,620
for height?
fent
Serial Heightmaxxer
- Joined
- Jan 19, 2026
- Posts
- 1,622
- Reputation
- 5,620
Roids don't work for height so just avoid them all tg
Sorb
Iron
- Joined
- Apr 10, 2026
- Posts
- 19
- Reputation
- 6
Yes tren doesn't it enhance mtor and enhances igf-1 signaling and also test doesn't it activate osteoblasts or some shi
Sorb
Iron
- Joined
- Apr 10, 2026
- Posts
- 19
- Reputation
- 6
Tbh idk but im on trt tren var and halo but got off halo till i get my liver ancillaries my goal is height and a summer physique
fent
Serial Heightmaxxer
- Joined
- Jan 19, 2026
- Posts
- 1,622
- Reputation
- 5,620
Tren maybe but also comes with other things
fent
Serial Heightmaxxer
- Joined
- Jan 19, 2026
- Posts
- 1,622
- Reputation
- 5,620
You'll get the physique, not the height.
Chondrocytes
We all ascending
- Joined
- Jan 21, 2026
- Posts
- 92
- Reputation
- 50
best thread on this forum tbh
LikableLoser
LikableLoser
Chondrocytes
We all ascending
- Joined
- Jan 21, 2026
- Posts
- 92
- Reputation
- 50
how would i stop bone maturation if using oxandrolone in my height stack.
fent
Serial Heightmaxxer
- Joined
- Jan 19, 2026
- Posts
- 1,622
- Reputation
- 5,620
You cant, dont use it
FoidSlayer
we will all ascend
- Joined
- Dec 15, 2025
- Posts
- 8,046
- Reputation
- 21,454
Fent always keeping it real, no bullshit. God I'm mirin so hard
LikableLoser
Iron
- Joined
- Mar 29, 2026
- Posts
- 41
- Reputation
- 87
I donated to this guy cause of this guide
birthdefect
pray to the purple powder
- Joined
- Jan 7, 2026
- Posts
- 1,712
- Reputation
- 3,006
its beautifulHeightmaxxing 202
By: Fent
____________________________________________________________________
Table of Contents:
FGFR3 inhibitors
CXXC5 inhibitors
SAG's
Vosoritide
Foxo4-dri
AAS for height growth
-Winstrol
-Anavar
-Halotestin
Tamoxifen
Socs2 inhibition
PTHrP analogues
SCO240
____________________________________________________________________
FGFR3 Inhibitors
What are FGFR3 Inhibitors
View attachment 45160
FGFR3 inhibitors are drugs that block the Fibroblast Growth Factor Receptor 3 protein FGFR3 normally acts like a brake on bone growth in the growth plates (the cartilage areas at the ends of long bones that allow you to get taller during childhood and adolescence). By inhibiting FGFR3, these drugs reduce that braking effect, allowing chondrocytes to proliferate and mature more freely. This leads to increased linear bone growth and greater height velocity especially in conditions like achondroplasia where the receptor is overactive due to a genetic mutation.
Types of FGFR3 inhibitors
•Infigratinib
•Erdafitinib
•Tyra-300 (dabogratinib)
•Loxo435
Infigratinib
Orally bioavailable, FGFR1-3 selective ATP-competitive TKI. It binds the ATP pocket of FGFR1, FGFR2, and FGFR3 (with much weaker activity on FGFR4 and VEGFR2). This dual inhibition hits both MAPK (hypertrophy) and STAT1 (proliferation) pathways downstream of FGFR3.
TL;DR
Once daily oral infigratinib (0.25 mg/kg) gave +1.74 cm/year (LS mean) or +2.10 cm/year extra annualized height velocity (AHV) vs placebo at 52 weeks. Absolute AHV reached 5.96 cm/year (highest reported in any ACH randomized trial). First drug to show statistically significant improvement in upper-to-lower body proportionality. Well tolerated; no FGFR1/2-related AEs or serious treatment-related events.
TL;DR
In ACH kids, highest dose produced +2.50 cm/year change in AHV from baseline at 18 months, +0.54 height Z-score, and improved proportionality (upper:lower ratio –0.12). Sustained effect, good safety.
TL;DR
Low dose infigratinib increased femur length, growth plate proliferative zone, and corrected disproportionate growth in Fgfr3 mutant mice.
Erdafitinib
Oral pan-FGFR (FGFR1-4) TKI. First FDA-approved pan-FGFR inhibitor (2019, for FGFR-altered urothelial cancer). Most potent against FGFR1, followed by FGFR3 > FGFR4 > FGFR2. Less selective than the others, so more off-target potential. (Not the best)
TL;DR
Pre-pubescent child with FGFR1-mutated glioma on erdafitinib showed rapid long-bone overgrowth, kyphoscoliosis, and spinal deformities within months
TL;DR
Cancer patients on erdafitinib had growth-factor and sex steroid independent acceleration of linear growth via FGFR3 inhibition. Proves the mechanism works for height but also carries severe risk.
Tyra-300
Oral, highly isoform-selective FGFR3 TKI (first-in-class FGFR3-selective). Designed with TYRA’s SNÅP platform to potently hit FGFR3 while sparing FGFR1/2/4 to minimize off-target toxicity. Once daily small molecule.
TL;DR
n wild-type mice + two FGFR3-driven models (ACH and hypochondroplasia), TYRA-300 significantly increased long-bone length (femur +3.7–5%, tibia +3.75–6%, etc.), nasoanal length, foramen magnum size, and improved skeletal proportionality and bone quality. First clear data showing FGFR3-selective inhibition works even in normal genetics. (Huge)
Loxo435
Oral, highly isoform-selective FGFR3 inhibitor (potent small-molecule TKI). Engineered by LOXO Oncology / Eli Lilly (goat) to maximize FGFR3 potency while minimizing off-target effects on other FGFRs and kinases for better safety.
There isnt too many studies i thought were worth showing however it looks promising alongside tyra-300 as a selective FGFR3 Inhibitor.
Biggest Con With Each Inhibitor:
Infigratinib:
• hyperphosphatemia
Erdafitinib:
•Rapid overgrowth (if retarded), Slipped capital femoral epiphysis and growth plate changes + premature fusion
Tyra-300:
•Unknown, as there is not enough studies+ pricing
Loxo435:
•same with tyra
CXXC5 Inhibitors
CXXC5
View attachment 45161
Acts as a negative regulator of human height by accelerating growth plate senescence and limiting longitudinal bone growth. It functions as a feedback inhibitor of the Wnt/β-catenin signaling pathway, which is paramount for maintaining chondrocyte proliferation and delaying senescence in the epiphyseal growth plates.
Induced by Wnt signaling itself and by estrogen (via estrogen receptor alpha), CXXC5 interacts with Dishevelled (DVL) to suppress β-catenin activity, thereby reducing chondrocyte proliferation, hypertrophy, and overall bone elongation.
In mouse models, CXXC5 knockout results in delayed growth plate senescence, increased tibial length, expanded proliferative and hypertrophic zones, and higher bone mass due to enhanced Wnt signaling. Pharmacological disruption of the CXXC5–DVL interaction has been shown to promote bone growth in preclinical studies, suggesting potential therapeutic applications for short stature caused by premature growth plate closure
The only CXXC5 inhib i think worth talking about is KY19382
KY19382
View attachment 45180
A small-molecule dual inhibitor that blocks CXXC5 (a protein that speeds up growth plate senescence/aging, which stops you from growing taller) from binding to dishevelled, while also inhibiting GSK3β.
This strongly activates the Wnt/β-catenin pathway inside growth-plate cartilage cells, delaying senescence, boosting chondrocyte proliferation, and keeping the growth plates active longer so bones can keep lengthening
Administration:
• Transdermally
- (not preferred imo)
• Subcutaneous Injection
“A functionally improved indirubin derivative, KY19382, elongated tibial length through delayed senescence and further activation of the growth plate in adolescent mice.”
Directly from the abstract; the full paper also states:
“Our results showed that KY19382 effectively increased the longitudinal growth of tibiae by delaying growth plate senescence through the accompanying promotion of chondrocyte proliferation and differentiation.”
Only con is theres no data in long term use
SAG21k and Purmorphamine
SAG21k and Purmorphamine
Small drug like molecules that directly switch on the Smoothened (SMO) receptor in the Hedgehog (Hh/Ihh/Shh) signaling pathway.
In the growth plates of growing bones, they completely bypass the normal control step where the Ihh signal inhibits Patched. This instantly activates Gli transcription factors.
The Result:
more epiphyseal skeletal stem cells (epSSCs) multiply in the resting zone, cartilage cells (chondrocytes) grow faster and form bigger clusters, a special environment is created that blocks Wnt signals to keep stem cells active, and the process of turning cartilage into bone speeds up.
Overall, this makes the growth plates thicker and leads to greater longitudinal bone lengthening
TL;DR
Systemic SAG21k (5 mg/kg/day IP for 7 days) in a mouse bone-defect model strongly enhanced early chondrogenesis via SHH pathway activation, creating more cartilage template that later ossified into greater bone
•Most likely cancer causing due to hedgehog pathway overactivation
•Price
•Sourcing
•You need a special delivery method for it
However, if you can source, afford and use it strategically so you dont get cancer, one of the greatest heightmaxx compounds
Vosoritide + CNP
What is CNP
CNP is a natural peptide hormone produced locally right inside your growth plates by chondrocytes (the cartilage cells that turn into bone CNP’s job is promoting endochondral bone growth (the exact process that makes your long bones femurs, tibias, etc longer during childhood/adolescence.)
CNP binds to its receptor NPR-B on chondrocytes, this ramps up intracellular cGMP (a signaling molecule).
cGMP then inhibits the MAPK/ERK pathway
Chondrocytes proliferate more, mature faster (hypertrophy), and produce more bone matrix and longer bones and increased height velocity.
Vosoritide
View attachment 45175
Vosoritide is a lab-made, longer lasting analog of CNP (39-amino-acid version engineered to resist quick breakdown). It’s given as a daily subcutaneous injection and is the first (and currently only) approved drug that directly harnesses this pathway for ACH. Vosoritide mimics CNP, binds NPR-B, raises cGMP, and counteracts FGFR3 signaling downstream (without touching the FGFR3 receptor itself meaning it is indirect).
TLDR 121 ACH kids (5–18 years). Vosoritide 15 µg/kg daily --> +1.57 cm/year extra AGV vs placebo (5.39 vs 3.81 cm/year at 52 weeks). Also +0.28 height Z-score.
Degrades VERY fast
Expensive compared to something like erda or infig.
FOXO4-DRI
FOXO4-DRI
View attachment 45172
FOXO4-DRI is a synthetic senolytic cell-penetrating peptide designed to selectively eliminate senescent cells (cells that stop dividing but secrete harmful inflammatory factors while healthy non-senescent cells are largely spared as it was designed to be selective)
How could it be used for height?
Growth plates naturally stop working (and height growth ends) because chondrocytes progressively enter senescence: they stop proliferating, secrete harmful inflammatory signals (the senescence-associated secretory phenotype, or SASP), and create a toxic microenvironment that further slows nearby healthy cells. This depletes the pool of resting-zone stem cells (epSSCs), shrinks the proliferative zone, reduces hypertrophic chondrocyte activity, and eventually leads to growth-plate thinning and fusion. Senescence is the main “programmed brake” on adult height.
FOXO4-DRI is designed to exploit a vulnerability unique to senescent cells: it disrupts the protective binding between FOXO4 and p53. In senescent chondrocytes (which rely heavily on this interaction to survive), this causes p53 to exit the nucleus, move to mitochondria, and trigger apoptosis (programmed cell death)
In Short
It would remove the accumulated senescent chondrocytes that are secreting SASP factors (IL-6, MMPs, etc.). Reduce inflammation and paracrine inhibition in the growth plate
Delay the overall “cell-counting” timer of senescence and postpone growth plate closure.
And allows epiphyseal skeletal stem cells and proliferative chondrocytes to expand, form longer columns, and maintain active endochondral ossification
However, I wouldnt personally take it.
AAS for height growth
Anavar:
(oxandrolone)
View attachment 45179
Mildest oral anabolic of the three. Temporarily boosts linear growth in some medical settings but advances bone age disproportionately. Lowest relative risk among the three for rapid closure, yet still causes net loss or no gain in adult height potential in normal teens.
Winstrol:
View attachment 45177
Animal data shows direct effects on growth plate chondrocytes
Halo:
(halotestin/fluoxymesterone)
View attachment 45178
Strongest/most potent androgen of the three (highly liver-toxic). Fastest bone maturation effect; FDA labels explicitly warn that androgens like this accelerate epiphyseal closure without compensatory linear growth in children. Highest risk of stunting height (if retarded)
TL;DR
Anavar increased height velocity but accelerated skeletal age more; some children lost predicted adult height (1.5–7.5 cm)
TL;DR
Winstrol affected proliferation of growth plate cells in adolescent rats (via estrogen receptor pathways). Shows direct impact on the growth plate but in a suppressed puberty model
TL;DR
Low-dose Halo increased growth velocity but required careful bone age monitoring. Final height exceeded predictions only in delayed cases
In conclusion
anavar has the most evidence for increased height velocity (despite me only showing one study for each).
however you have to be careful to not cause alot of bone maturation which isnt too hard. Best of luck
When you take any AAS even at a low dose the drug travels through your bloodstream and reaches the growth plates. There it binds directly to androgen receptors on the chondrocytes, the cartilage cells responsible for making new bone. These androgen receptors do not care if the dose is high or low; they simply respond to the presence of the molecule. Their job is to accelerate terminal differentiation, basically telling the chondrocytes to stop dividing and to mature faster into bone.
Therefore it is utter cope
for the help.
Tamoxifen
Tamoxifen:
View attachment 45173
selective estrogen receptor modulator (SERM), a drug that binds to estrogen receptors (mainly ERα and ERβ) and can act as either an estrogen blocker (antagonist) or estrogen mimic (agonist) depending on the tissue. It is FDA-approved primarily for treating and preventing estrogen receptor-positive breast cancer in adults, and it is also used off label for conditions like gynecomastia
How Tamoxifen Works
Tamoxifen competes directly with estradiol (E2) for binding to estrogen receptors in target cells
In growth-plate chondrocytes (cartilage cells responsible for bone lengthening), it can exert anti-estrogenic effects by inhibiting specific downstream signaling pathways triggered by E2, such as protein kinase C (PKC). This modulates chondrocyte differentiation and profileration
TL;DR
7 short pubertal boys (average age ~15) treated with tamoxifen (twice daily for 6 months–4 years; some also on GH). Tamoxifen significantly slowed skeletal maturation and increased predicted adult height by 4 inches (from ~5'6" to ~5'10") with no negative effects on sexual maturation or puberty progression
However authors called for larger prospective studies to confirm if this translates to actual final height gain
TL;DR
In vivo study in young male rats given clinically relevant doses for 4 weeks (followed by 14-week recovery). Tamoxifen caused persistent shorter tibia and reduced cortical bone size/strength, increased chondrocyte apoptosis, narrowed growth plates, and lowered serum IGF-1 levels
Socs2 inhibition
SOCS2:
(Suppressor of Cytokine Signaling 2)
View attachment 45174
Is a protein encoded by the SOCS2 gene in humans. It belongs to the SOCS family of intracellular proteins that act as negative feedback regulators of cytokine signaling, primarily through the JAK/STAT pathway
SOCS2 is a key negative regulator of growth hormone (GH) signaling. It binds to the phosphorylated GH receptor (GHR), promotes its ubiquitination and degradation (via the ECS ubiquitin ligase complex), and thereby dampens downstream STAT5 activation and IGF-1 production. This limits the anabolic and growth-promoting effects of GH/IGF-1
Which basically means SOCS2 is an inhibitor of GH Because SOCS2 inhibits GH signaling, reducing or blocking SOCS2 function removes this brake. This leads to enhanced GH receptor sensitivity, prolonged STAT5 signaling, higher local and systemic IGF-1, and increased linear bone growth. They are kinda like FGFR3 inhibitors.
•Significant linear growth enhancement
•Amplifies exogenous GH
•Targeted and reversible
•Metabolic risks from chronic GH/IGF-1 hyper-signaling: Potential insulin resistance,ect
IGF-1 is mitogenic; SOCS2 has complex roles in cancer (sometimes tumor-suppressive, sometimes pro-tumor in specific tissues)
•Potential organ enlargement
•Not too many ways to actually inhibit
TL;DR
mice grew 30–40% larger than wild-type, increased body weight, long-bone length, and proportional enlargement of most organs
TL;DR
Naturally occurring deletion of SOCS2 increased growth significantly however shortened lifespan in some mice
TL;DR
Mutation in SOCS2 linked to gigantism (increased height/weight) in human model
PTHrP analogues
PTHrP analogues:
View attachment 45171
Synthetic peptides that mimic parathyroid hormone-related protein (PTHrP), a key local regulator of the growth plate. The main clinically available ones are abaloparatide (Tymlos; a modified PTHrP(1-34) analogue) and teriparatide (Forteo; recombinant human PTH(1-34)). Both bind and activate the same receptor (PTH1R) that native PTHrP uses in chondrocytes, but they are given as daily subcutaneous injections.
In the epiphyseal growth plate, PTHrP is produced locally by resting-zone chondrocytes (including skeletal stem cells). It acts via PTH1R to Keep chondrocytes in the proliferative state, delay their maturation into hypertrophic cells and maintain the Ihh–PTHrP feedback loop that controls the pace of endochondral ossification
Intermittent (once-daily) dosing of PTHrP/PTH analogues mimics this natural signaling in a pulsed way that strongly stimulates bone formation meaning these compounds would:
•Expand the proliferative and hypertrophic zones
Increase chondrocyte columns and cartilage thickness
•Prolong active growth before senescence/closure
In short increasing height
Abalo and Teri Comparison:
Abalo pros:
•Designed to copy PTHrP’s natural growth-plate role more closely
•Potentially cleaner anabolic effect with less unwanted resorption or calcium spikes
•Rat data suggest stronger stimulation of cartilage thickness and site-specific bone lengthening
Abalo cons:
•Far less real-world pediatric data
osteosarcoma risk as seen in high dose rat studies
Teri pros:
•Decades more safety/efficacy data in humans
Proven to stimulate longitudinal growth in animal models
Teri cons:
•more resorption and higher hypercalcemia risk
Less selective
In conclusion abalo would be the better choice here however it has alot less research so, its down to preference.
SCO240
SCO240:
An oral small-molecule antagonist of somatostatin receptor type 5 (SSTR5). It is a first in class compound designed to stimulate endogenous GH secretion
from the pituitary gland
Somatostatin normally inhibits GH release by binding to SSTR5 on pituitary somatotroph cells. SCO-240 blocks this receptor selectively, removing the inhibition and allowing the body to release more of its own GH in a more physiological (pulsatile) pattern — without affecting other pituitary hormones (prolactin, TSH, ACTH, FSH, LH).
By boosting natural GH secretion, SCO-240 increases downstream IGF-1 production, which directly promotes chondrocyte proliferation and hypertrophy leading to increased growth velocity.
•Oral (convenience)
•Highly selective for GH
•Physiological GH release: mimics natural pulsatile pattern more closely than injected rhGH.
•Only phase 1 data in healthy adults; no published efficacy or height data in children with GHD or short stature yet.
•Basic GH excess risks (insulin resistance ect)
•Sourcing + Prices
•Limited data
TL;DR
Caused robust, dose-dependent GH secretion (comparable to therapeutic rhGH levels) with no effect on other pituitary hormones, insulin, or GLP-1.
Growth Plates
Resting Zone
This is the top layer of the growth plate, right near the end of the bone. The cells here are mostly stagnant and don’t divide much. They act like a stock of spare cartilage cells. Their job is to slowly supply new cells to the layers below when needed.
Proliferating Zone
This is the busy factory zone. The cartilage cells divide quickly and stack up in neat columns, like coins piled on top of each other. Every time they multiply, they add a bit more length to the bone. This is where most of the actual growth in height happens. It’s the most active part of the growth plate.
Hypertrophic Zone
In this zone, the cells stop dividing and start getting much bigger. As they grow larger, they help push the bone longer. Then they prepare the area by making the cartilage matrix harder. Eventually the cells die off, and the hardened cartilage gets replaced by real bone. This is the last step before the cartilage turns into solid bone.
____________________________________________________________________
Conclusion:
Leave a rep if you enjoyed
dept14
logical black guy
- Joined
- Mar 11, 2026
- Posts
- 157
- Reputation
- 275
fireHeightmaxxing 202
By: Fent
____________________________________________________________________
Table of Contents:
FGFR3 inhibitors
CXXC5 inhibitors
SAG's
Vosoritide
Foxo4-dri
AAS for height growth
-Winstrol
-Anavar
-Halotestin
Tamoxifen
Socs2 inhibition
PTHrP analogues
SCO240
____________________________________________________________________
FGFR3 Inhibitors
What are FGFR3 Inhibitors
View attachment 45160
FGFR3 inhibitors are drugs that block the Fibroblast Growth Factor Receptor 3 protein FGFR3 normally acts like a brake on bone growth in the growth plates (the cartilage areas at the ends of long bones that allow you to get taller during childhood and adolescence). By inhibiting FGFR3, these drugs reduce that braking effect, allowing chondrocytes to proliferate and mature more freely. This leads to increased linear bone growth and greater height velocity especially in conditions like achondroplasia where the receptor is overactive due to a genetic mutation.
Types of FGFR3 inhibitors
•Infigratinib
•Erdafitinib
•Tyra-300 (dabogratinib)
•Loxo435
Infigratinib
Orally bioavailable, FGFR1-3 selective ATP-competitive TKI. It binds the ATP pocket of FGFR1, FGFR2, and FGFR3 (with much weaker activity on FGFR4 and VEGFR2). This dual inhibition hits both MAPK (hypertrophy) and STAT1 (proliferation) pathways downstream of FGFR3.
TL;DR
Once daily oral infigratinib (0.25 mg/kg) gave +1.74 cm/year (LS mean) or +2.10 cm/year extra annualized height velocity (AHV) vs placebo at 52 weeks. Absolute AHV reached 5.96 cm/year (highest reported in any ACH randomized trial). First drug to show statistically significant improvement in upper-to-lower body proportionality. Well tolerated; no FGFR1/2-related AEs or serious treatment-related events.
TL;DR
In ACH kids, highest dose produced +2.50 cm/year change in AHV from baseline at 18 months, +0.54 height Z-score, and improved proportionality (upper:lower ratio –0.12). Sustained effect, good safety.
TL;DR
Low dose infigratinib increased femur length, growth plate proliferative zone, and corrected disproportionate growth in Fgfr3 mutant mice.
Erdafitinib
Oral pan-FGFR (FGFR1-4) TKI. First FDA-approved pan-FGFR inhibitor (2019, for FGFR-altered urothelial cancer). Most potent against FGFR1, followed by FGFR3 > FGFR4 > FGFR2. Less selective than the others, so more off-target potential. (Not the best)
TL;DR
Pre-pubescent child with FGFR1-mutated glioma on erdafitinib showed rapid long-bone overgrowth, kyphoscoliosis, and spinal deformities within months
TL;DR
Cancer patients on erdafitinib had growth-factor and sex steroid independent acceleration of linear growth via FGFR3 inhibition. Proves the mechanism works for height but also carries severe risk.
Tyra-300
Oral, highly isoform-selective FGFR3 TKI (first-in-class FGFR3-selective). Designed with TYRA’s SNÅP platform to potently hit FGFR3 while sparing FGFR1/2/4 to minimize off-target toxicity. Once daily small molecule.
TL;DR
n wild-type mice + two FGFR3-driven models (ACH and hypochondroplasia), TYRA-300 significantly increased long-bone length (femur +3.7–5%, tibia +3.75–6%, etc.), nasoanal length, foramen magnum size, and improved skeletal proportionality and bone quality. First clear data showing FGFR3-selective inhibition works even in normal genetics. (Huge)
Loxo435
Oral, highly isoform-selective FGFR3 inhibitor (potent small-molecule TKI). Engineered by LOXO Oncology / Eli Lilly (goat) to maximize FGFR3 potency while minimizing off-target effects on other FGFRs and kinases for better safety.
There isnt too many studies i thought were worth showing however it looks promising alongside tyra-300 as a selective FGFR3 Inhibitor.
Biggest Con With Each Inhibitor:
Infigratinib:
• hyperphosphatemia
Erdafitinib:
•Rapid overgrowth (if retarded), Slipped capital femoral epiphysis and growth plate changes + premature fusion
Tyra-300:
•Unknown, as there is not enough studies+ pricing
Loxo435:
•same with tyra
CXXC5 Inhibitors
CXXC5
View attachment 45161
Acts as a negative regulator of human height by accelerating growth plate senescence and limiting longitudinal bone growth. It functions as a feedback inhibitor of the Wnt/β-catenin signaling pathway, which is paramount for maintaining chondrocyte proliferation and delaying senescence in the epiphyseal growth plates.
Induced by Wnt signaling itself and by estrogen (via estrogen receptor alpha), CXXC5 interacts with Dishevelled (DVL) to suppress β-catenin activity, thereby reducing chondrocyte proliferation, hypertrophy, and overall bone elongation.
In mouse models, CXXC5 knockout results in delayed growth plate senescence, increased tibial length, expanded proliferative and hypertrophic zones, and higher bone mass due to enhanced Wnt signaling. Pharmacological disruption of the CXXC5–DVL interaction has been shown to promote bone growth in preclinical studies, suggesting potential therapeutic applications for short stature caused by premature growth plate closure
The only CXXC5 inhib i think worth talking about is KY19382
KY19382
View attachment 45180
A small-molecule dual inhibitor that blocks CXXC5 (a protein that speeds up growth plate senescence/aging, which stops you from growing taller) from binding to dishevelled, while also inhibiting GSK3β.
This strongly activates the Wnt/β-catenin pathway inside growth-plate cartilage cells, delaying senescence, boosting chondrocyte proliferation, and keeping the growth plates active longer so bones can keep lengthening
Administration:
• Transdermally
- (not preferred imo)
• Subcutaneous Injection
“A functionally improved indirubin derivative, KY19382, elongated tibial length through delayed senescence and further activation of the growth plate in adolescent mice.”
Directly from the abstract; the full paper also states:
“Our results showed that KY19382 effectively increased the longitudinal growth of tibiae by delaying growth plate senescence through the accompanying promotion of chondrocyte proliferation and differentiation.”
Only con is theres no data in long term use
SAG21k and Purmorphamine
SAG21k and Purmorphamine
Small drug like molecules that directly switch on the Smoothened (SMO) receptor in the Hedgehog (Hh/Ihh/Shh) signaling pathway.
In the growth plates of growing bones, they completely bypass the normal control step where the Ihh signal inhibits Patched. This instantly activates Gli transcription factors.
The Result:
more epiphyseal skeletal stem cells (epSSCs) multiply in the resting zone, cartilage cells (chondrocytes) grow faster and form bigger clusters, a special environment is created that blocks Wnt signals to keep stem cells active, and the process of turning cartilage into bone speeds up.
Overall, this makes the growth plates thicker and leads to greater longitudinal bone lengthening
TL;DR
Systemic SAG21k (5 mg/kg/day IP for 7 days) in a mouse bone-defect model strongly enhanced early chondrogenesis via SHH pathway activation, creating more cartilage template that later ossified into greater bone
•Most likely cancer causing due to hedgehog pathway overactivation
•Price
•Sourcing
•You need a special delivery method for it
However, if you can source, afford and use it strategically so you dont get cancer, one of the greatest heightmaxx compounds
Vosoritide + CNP
What is CNP
CNP is a natural peptide hormone produced locally right inside your growth plates by chondrocytes (the cartilage cells that turn into bone CNP’s job is promoting endochondral bone growth (the exact process that makes your long bones femurs, tibias, etc longer during childhood/adolescence.)
CNP binds to its receptor NPR-B on chondrocytes, this ramps up intracellular cGMP (a signaling molecule).
cGMP then inhibits the MAPK/ERK pathway
Chondrocytes proliferate more, mature faster (hypertrophy), and produce more bone matrix and longer bones and increased height velocity.
Vosoritide
View attachment 45175
Vosoritide is a lab-made, longer lasting analog of CNP (39-amino-acid version engineered to resist quick breakdown). It’s given as a daily subcutaneous injection and is the first (and currently only) approved drug that directly harnesses this pathway for ACH. Vosoritide mimics CNP, binds NPR-B, raises cGMP, and counteracts FGFR3 signaling downstream (without touching the FGFR3 receptor itself meaning it is indirect).
TLDR 121 ACH kids (5–18 years). Vosoritide 15 µg/kg daily --> +1.57 cm/year extra AGV vs placebo (5.39 vs 3.81 cm/year at 52 weeks). Also +0.28 height Z-score.
Degrades VERY fast
Expensive compared to something like erda or infig.
FOXO4-DRI
FOXO4-DRI
View attachment 45172
FOXO4-DRI is a synthetic senolytic cell-penetrating peptide designed to selectively eliminate senescent cells (cells that stop dividing but secrete harmful inflammatory factors while healthy non-senescent cells are largely spared as it was designed to be selective)
How could it be used for height?
Growth plates naturally stop working (and height growth ends) because chondrocytes progressively enter senescence: they stop proliferating, secrete harmful inflammatory signals (the senescence-associated secretory phenotype, or SASP), and create a toxic microenvironment that further slows nearby healthy cells. This depletes the pool of resting-zone stem cells (epSSCs), shrinks the proliferative zone, reduces hypertrophic chondrocyte activity, and eventually leads to growth-plate thinning and fusion. Senescence is the main “programmed brake” on adult height.
FOXO4-DRI is designed to exploit a vulnerability unique to senescent cells: it disrupts the protective binding between FOXO4 and p53. In senescent chondrocytes (which rely heavily on this interaction to survive), this causes p53 to exit the nucleus, move to mitochondria, and trigger apoptosis (programmed cell death)
In Short
It would remove the accumulated senescent chondrocytes that are secreting SASP factors (IL-6, MMPs, etc.). Reduce inflammation and paracrine inhibition in the growth plate
Delay the overall “cell-counting” timer of senescence and postpone growth plate closure.
And allows epiphyseal skeletal stem cells and proliferative chondrocytes to expand, form longer columns, and maintain active endochondral ossification
However, I wouldnt personally take it.
AAS for height growth
Anavar:
(oxandrolone)
View attachment 45179
Mildest oral anabolic of the three. Temporarily boosts linear growth in some medical settings but advances bone age disproportionately. Lowest relative risk among the three for rapid closure, yet still causes net loss or no gain in adult height potential in normal teens.
Winstrol:
View attachment 45177
Animal data shows direct effects on growth plate chondrocytes
Halo:
(halotestin/fluoxymesterone)
View attachment 45178
Strongest/most potent androgen of the three (highly liver-toxic). Fastest bone maturation effect; FDA labels explicitly warn that androgens like this accelerate epiphyseal closure without compensatory linear growth in children. Highest risk of stunting height (if retarded)
TL;DR
Anavar increased height velocity but accelerated skeletal age more; some children lost predicted adult height (1.5–7.5 cm)
TL;DR
Winstrol affected proliferation of growth plate cells in adolescent rats (via estrogen receptor pathways). Shows direct impact on the growth plate but in a suppressed puberty model
TL;DR
Low-dose Halo increased growth velocity but required careful bone age monitoring. Final height exceeded predictions only in delayed cases
In conclusion
anavar has the most evidence for increased height velocity (despite me only showing one study for each).
however you have to be careful to not cause alot of bone maturation which isnt too hard. Best of luck
When you take any AAS even at a low dose the drug travels through your bloodstream and reaches the growth plates. There it binds directly to androgen receptors on the chondrocytes, the cartilage cells responsible for making new bone. These androgen receptors do not care if the dose is high or low; they simply respond to the presence of the molecule. Their job is to accelerate terminal differentiation, basically telling the chondrocytes to stop dividing and to mature faster into bone.
Therefore it is utter cope
for the help.
Tamoxifen
Tamoxifen:
View attachment 45173
selective estrogen receptor modulator (SERM), a drug that binds to estrogen receptors (mainly ERα and ERβ) and can act as either an estrogen blocker (antagonist) or estrogen mimic (agonist) depending on the tissue. It is FDA-approved primarily for treating and preventing estrogen receptor-positive breast cancer in adults, and it is also used off label for conditions like gynecomastia
How Tamoxifen Works
Tamoxifen competes directly with estradiol (E2) for binding to estrogen receptors in target cells
In growth-plate chondrocytes (cartilage cells responsible for bone lengthening), it can exert anti-estrogenic effects by inhibiting specific downstream signaling pathways triggered by E2, such as protein kinase C (PKC). This modulates chondrocyte differentiation and profileration
TL;DR
7 short pubertal boys (average age ~15) treated with tamoxifen (twice daily for 6 months–4 years; some also on GH). Tamoxifen significantly slowed skeletal maturation and increased predicted adult height by 4 inches (from ~5'6" to ~5'10") with no negative effects on sexual maturation or puberty progression
However authors called for larger prospective studies to confirm if this translates to actual final height gain
TL;DR
In vivo study in young male rats given clinically relevant doses for 4 weeks (followed by 14-week recovery). Tamoxifen caused persistent shorter tibia and reduced cortical bone size/strength, increased chondrocyte apoptosis, narrowed growth plates, and lowered serum IGF-1 levels
Socs2 inhibition
SOCS2:
(Suppressor of Cytokine Signaling 2)
View attachment 45174
Is a protein encoded by the SOCS2 gene in humans. It belongs to the SOCS family of intracellular proteins that act as negative feedback regulators of cytokine signaling, primarily through the JAK/STAT pathway
SOCS2 is a key negative regulator of growth hormone (GH) signaling. It binds to the phosphorylated GH receptor (GHR), promotes its ubiquitination and degradation (via the ECS ubiquitin ligase complex), and thereby dampens downstream STAT5 activation and IGF-1 production. This limits the anabolic and growth-promoting effects of GH/IGF-1
Which basically means SOCS2 is an inhibitor of GH Because SOCS2 inhibits GH signaling, reducing or blocking SOCS2 function removes this brake. This leads to enhanced GH receptor sensitivity, prolonged STAT5 signaling, higher local and systemic IGF-1, and increased linear bone growth. They are kinda like FGFR3 inhibitors.
•Significant linear growth enhancement
•Amplifies exogenous GH
•Targeted and reversible
•Metabolic risks from chronic GH/IGF-1 hyper-signaling: Potential insulin resistance,ect
IGF-1 is mitogenic; SOCS2 has complex roles in cancer (sometimes tumor-suppressive, sometimes pro-tumor in specific tissues)
•Potential organ enlargement
•Not too many ways to actually inhibit
TL;DR
mice grew 30–40% larger than wild-type, increased body weight, long-bone length, and proportional enlargement of most organs
TL;DR
Naturally occurring deletion of SOCS2 increased growth significantly however shortened lifespan in some mice
TL;DR
Mutation in SOCS2 linked to gigantism (increased height/weight) in human model
PTHrP analogues
PTHrP analogues:
View attachment 45171
Synthetic peptides that mimic parathyroid hormone-related protein (PTHrP), a key local regulator of the growth plate. The main clinically available ones are abaloparatide (Tymlos; a modified PTHrP(1-34) analogue) and teriparatide (Forteo; recombinant human PTH(1-34)). Both bind and activate the same receptor (PTH1R) that native PTHrP uses in chondrocytes, but they are given as daily subcutaneous injections.
In the epiphyseal growth plate, PTHrP is produced locally by resting-zone chondrocytes (including skeletal stem cells). It acts via PTH1R to Keep chondrocytes in the proliferative state, delay their maturation into hypertrophic cells and maintain the Ihh–PTHrP feedback loop that controls the pace of endochondral ossification
Intermittent (once-daily) dosing of PTHrP/PTH analogues mimics this natural signaling in a pulsed way that strongly stimulates bone formation meaning these compounds would:
•Expand the proliferative and hypertrophic zones
Increase chondrocyte columns and cartilage thickness
•Prolong active growth before senescence/closure
In short increasing height
Abalo and Teri Comparison:
Abalo pros:
•Designed to copy PTHrP’s natural growth-plate role more closely
•Potentially cleaner anabolic effect with less unwanted resorption or calcium spikes
•Rat data suggest stronger stimulation of cartilage thickness and site-specific bone lengthening
Abalo cons:
•Far less real-world pediatric data
osteosarcoma risk as seen in high dose rat studies
Teri pros:
•Decades more safety/efficacy data in humans
Proven to stimulate longitudinal growth in animal models
Teri cons:
•more resorption and higher hypercalcemia risk
Less selective
In conclusion abalo would be the better choice here however it has alot less research so, its down to preference.
SCO240
SCO240:
An oral small-molecule antagonist of somatostatin receptor type 5 (SSTR5). It is a first in class compound designed to stimulate endogenous GH secretion
from the pituitary gland
Somatostatin normally inhibits GH release by binding to SSTR5 on pituitary somatotroph cells. SCO-240 blocks this receptor selectively, removing the inhibition and allowing the body to release more of its own GH in a more physiological (pulsatile) pattern — without affecting other pituitary hormones (prolactin, TSH, ACTH, FSH, LH).
By boosting natural GH secretion, SCO-240 increases downstream IGF-1 production, which directly promotes chondrocyte proliferation and hypertrophy leading to increased growth velocity.
•Oral (convenience)
•Highly selective for GH
•Physiological GH release: mimics natural pulsatile pattern more closely than injected rhGH.
•Only phase 1 data in healthy adults; no published efficacy or height data in children with GHD or short stature yet.
•Basic GH excess risks (insulin resistance ect)
•Sourcing + Prices
•Limited data
TL;DR
Caused robust, dose-dependent GH secretion (comparable to therapeutic rhGH levels) with no effect on other pituitary hormones, insulin, or GLP-1.
Growth Plates
Resting Zone
This is the top layer of the growth plate, right near the end of the bone. The cells here are mostly stagnant and don’t divide much. They act like a stock of spare cartilage cells. Their job is to slowly supply new cells to the layers below when needed.
Proliferating Zone
This is the busy factory zone. The cartilage cells divide quickly and stack up in neat columns, like coins piled on top of each other. Every time they multiply, they add a bit more length to the bone. This is where most of the actual growth in height happens. It’s the most active part of the growth plate.
Hypertrophic Zone
In this zone, the cells stop dividing and start getting much bigger. As they grow larger, they help push the bone longer. Then they prepare the area by making the cartilage matrix harder. Eventually the cells die off, and the hardened cartilage gets replaced by real bone. This is the last step before the cartilage turns into solid bone.
____________________________________________________________________
Conclusion:
Leave a rep if you enjoyed
Slopslayyer69
Iron
- Joined
- May 2, 2026
- Posts
- 26
- Reputation
- 6
How long did it take you to research all of this lol
- Joined
- Jan 6, 2026
- Posts
- 147
- Reputation
- 77
Mogger
fent
Serial Heightmaxxer
- Joined
- Jan 19, 2026
- Posts
- 1,622
- Reputation
- 5,620
fent
Serial Heightmaxxer
- Joined
- Jan 19, 2026
- Posts
- 1,622
- Reputation
- 5,620
Selective inhibitors like TYRA or Loxo but theyre gonna cost you a kidney
FS51
Gone till the summer
- Joined
- Dec 25, 2025
- Posts
- 3,829
- Reputation
- 9,356
Sexy ass guide, definetly deserved botb spotHeightmaxxing 202
By: Fent
____________________________________________________________________
Table of Contents:
FGFR3 inhibitors
CXXC5 inhibitors
SAG's
Vosoritide
Foxo4-dri
AAS for height growth
-Winstrol
-Anavar
-Halotestin
Tamoxifen
Socs2 inhibition
PTHrP analogues
SCO240
____________________________________________________________________
FGFR3 Inhibitors
What are FGFR3 Inhibitors
View attachment 45160
FGFR3 inhibitors are drugs that block the Fibroblast Growth Factor Receptor 3 protein FGFR3 normally acts like a brake on bone growth in the growth plates (the cartilage areas at the ends of long bones that allow you to get taller during childhood and adolescence). By inhibiting FGFR3, these drugs reduce that braking effect, allowing chondrocytes to proliferate and mature more freely. This leads to increased linear bone growth and greater height velocity especially in conditions like achondroplasia where the receptor is overactive due to a genetic mutation.
Types of FGFR3 inhibitors
•Infigratinib
•Erdafitinib
•Tyra-300 (dabogratinib)
•Loxo435
Infigratinib
Orally bioavailable, FGFR1-3 selective ATP-competitive TKI. It binds the ATP pocket of FGFR1, FGFR2, and FGFR3 (with much weaker activity on FGFR4 and VEGFR2). This dual inhibition hits both MAPK (hypertrophy) and STAT1 (proliferation) pathways downstream of FGFR3.
TL;DR
Once daily oral infigratinib (0.25 mg/kg) gave +1.74 cm/year (LS mean) or +2.10 cm/year extra annualized height velocity (AHV) vs placebo at 52 weeks. Absolute AHV reached 5.96 cm/year (highest reported in any ACH randomized trial). First drug to show statistically significant improvement in upper-to-lower body proportionality. Well tolerated; no FGFR1/2-related AEs or serious treatment-related events.
TL;DR
In ACH kids, highest dose produced +2.50 cm/year change in AHV from baseline at 18 months, +0.54 height Z-score, and improved proportionality (upper:lower ratio –0.12). Sustained effect, good safety.
TL;DR
Low dose infigratinib increased femur length, growth plate proliferative zone, and corrected disproportionate growth in Fgfr3 mutant mice.
Erdafitinib
Oral pan-FGFR (FGFR1-4) TKI. First FDA-approved pan-FGFR inhibitor (2019, for FGFR-altered urothelial cancer). Most potent against FGFR1, followed by FGFR3 > FGFR4 > FGFR2. Less selective than the others, so more off-target potential. (Not the best)
TL;DR
Pre-pubescent child with FGFR1-mutated glioma on erdafitinib showed rapid long-bone overgrowth, kyphoscoliosis, and spinal deformities within months
TL;DR
Cancer patients on erdafitinib had growth-factor and sex steroid independent acceleration of linear growth via FGFR3 inhibition. Proves the mechanism works for height but also carries severe risk.
Tyra-300
Oral, highly isoform-selective FGFR3 TKI (first-in-class FGFR3-selective). Designed with TYRA’s SNÅP platform to potently hit FGFR3 while sparing FGFR1/2/4 to minimize off-target toxicity. Once daily small molecule.
TL;DR
n wild-type mice + two FGFR3-driven models (ACH and hypochondroplasia), TYRA-300 significantly increased long-bone length (femur +3.7–5%, tibia +3.75–6%, etc.), nasoanal length, foramen magnum size, and improved skeletal proportionality and bone quality. First clear data showing FGFR3-selective inhibition works even in normal genetics. (Huge)
Loxo435
Oral, highly isoform-selective FGFR3 inhibitor (potent small-molecule TKI). Engineered by LOXO Oncology / Eli Lilly (goat) to maximize FGFR3 potency while minimizing off-target effects on other FGFRs and kinases for better safety.
There isnt too many studies i thought were worth showing however it looks promising alongside tyra-300 as a selective FGFR3 Inhibitor.
Biggest Con With Each Inhibitor:
Infigratinib:
• hyperphosphatemia
Erdafitinib:
•Rapid overgrowth (if retarded), Slipped capital femoral epiphysis and growth plate changes + premature fusion
Tyra-300:
•Unknown, as there is not enough studies+ pricing
Loxo435:
•same with tyra
CXXC5 Inhibitors
CXXC5
View attachment 45161
Acts as a negative regulator of human height by accelerating growth plate senescence and limiting longitudinal bone growth. It functions as a feedback inhibitor of the Wnt/β-catenin signaling pathway, which is paramount for maintaining chondrocyte proliferation and delaying senescence in the epiphyseal growth plates.
Induced by Wnt signaling itself and by estrogen (via estrogen receptor alpha), CXXC5 interacts with Dishevelled (DVL) to suppress β-catenin activity, thereby reducing chondrocyte proliferation, hypertrophy, and overall bone elongation.
In mouse models, CXXC5 knockout results in delayed growth plate senescence, increased tibial length, expanded proliferative and hypertrophic zones, and higher bone mass due to enhanced Wnt signaling. Pharmacological disruption of the CXXC5–DVL interaction has been shown to promote bone growth in preclinical studies, suggesting potential therapeutic applications for short stature caused by premature growth plate closure
The only CXXC5 inhib i think worth talking about is KY19382
KY19382
View attachment 45180
A small-molecule dual inhibitor that blocks CXXC5 (a protein that speeds up growth plate senescence/aging, which stops you from growing taller) from binding to dishevelled, while also inhibiting GSK3β.
This strongly activates the Wnt/β-catenin pathway inside growth-plate cartilage cells, delaying senescence, boosting chondrocyte proliferation, and keeping the growth plates active longer so bones can keep lengthening
Administration:
• Transdermally
- (not preferred imo)
• Subcutaneous Injection
“A functionally improved indirubin derivative, KY19382, elongated tibial length through delayed senescence and further activation of the growth plate in adolescent mice.”
Directly from the abstract; the full paper also states:
“Our results showed that KY19382 effectively increased the longitudinal growth of tibiae by delaying growth plate senescence through the accompanying promotion of chondrocyte proliferation and differentiation.”
Only con is theres no data in long term use
SAG21k and Purmorphamine
SAG21k and Purmorphamine
Small drug like molecules that directly switch on the Smoothened (SMO) receptor in the Hedgehog (Hh/Ihh/Shh) signaling pathway.
In the growth plates of growing bones, they completely bypass the normal control step where the Ihh signal inhibits Patched. This instantly activates Gli transcription factors.
The Result:
more epiphyseal skeletal stem cells (epSSCs) multiply in the resting zone, cartilage cells (chondrocytes) grow faster and form bigger clusters, a special environment is created that blocks Wnt signals to keep stem cells active, and the process of turning cartilage into bone speeds up.
Overall, this makes the growth plates thicker and leads to greater longitudinal bone lengthening
TL;DR
Systemic SAG21k (5 mg/kg/day IP for 7 days) in a mouse bone-defect model strongly enhanced early chondrogenesis via SHH pathway activation, creating more cartilage template that later ossified into greater bone
•Most likely cancer causing due to hedgehog pathway overactivation
•Price
•Sourcing
•You need a special delivery method for it
However, if you can source, afford and use it strategically so you dont get cancer, one of the greatest heightmaxx compounds
Vosoritide + CNP
What is CNP
CNP is a natural peptide hormone produced locally right inside your growth plates by chondrocytes (the cartilage cells that turn into bone CNP’s job is promoting endochondral bone growth (the exact process that makes your long bones femurs, tibias, etc longer during childhood/adolescence.)
CNP binds to its receptor NPR-B on chondrocytes, this ramps up intracellular cGMP (a signaling molecule).
cGMP then inhibits the MAPK/ERK pathway
Chondrocytes proliferate more, mature faster (hypertrophy), and produce more bone matrix and longer bones and increased height velocity.
Vosoritide
View attachment 45175
Vosoritide is a lab-made, longer lasting analog of CNP (39-amino-acid version engineered to resist quick breakdown). It’s given as a daily subcutaneous injection and is the first (and currently only) approved drug that directly harnesses this pathway for ACH. Vosoritide mimics CNP, binds NPR-B, raises cGMP, and counteracts FGFR3 signaling downstream (without touching the FGFR3 receptor itself meaning it is indirect).
TLDR 121 ACH kids (5–18 years). Vosoritide 15 µg/kg daily --> +1.57 cm/year extra AGV vs placebo (5.39 vs 3.81 cm/year at 52 weeks). Also +0.28 height Z-score.
Degrades VERY fast
Expensive compared to something like erda or infig.
FOXO4-DRI
FOXO4-DRI
View attachment 45172
FOXO4-DRI is a synthetic senolytic cell-penetrating peptide designed to selectively eliminate senescent cells (cells that stop dividing but secrete harmful inflammatory factors while healthy non-senescent cells are largely spared as it was designed to be selective)
How could it be used for height?
Growth plates naturally stop working (and height growth ends) because chondrocytes progressively enter senescence: they stop proliferating, secrete harmful inflammatory signals (the senescence-associated secretory phenotype, or SASP), and create a toxic microenvironment that further slows nearby healthy cells. This depletes the pool of resting-zone stem cells (epSSCs), shrinks the proliferative zone, reduces hypertrophic chondrocyte activity, and eventually leads to growth-plate thinning and fusion. Senescence is the main “programmed brake” on adult height.
FOXO4-DRI is designed to exploit a vulnerability unique to senescent cells: it disrupts the protective binding between FOXO4 and p53. In senescent chondrocytes (which rely heavily on this interaction to survive), this causes p53 to exit the nucleus, move to mitochondria, and trigger apoptosis (programmed cell death)
In Short
It would remove the accumulated senescent chondrocytes that are secreting SASP factors (IL-6, MMPs, etc.). Reduce inflammation and paracrine inhibition in the growth plate
Delay the overall “cell-counting” timer of senescence and postpone growth plate closure.
And allows epiphyseal skeletal stem cells and proliferative chondrocytes to expand, form longer columns, and maintain active endochondral ossification
However, I wouldnt personally take it.
AAS for height growth
Anavar:
(oxandrolone)
View attachment 45179
Mildest oral anabolic of the three. Temporarily boosts linear growth in some medical settings but advances bone age disproportionately. Lowest relative risk among the three for rapid closure, yet still causes net loss or no gain in adult height potential in normal teens.
Winstrol:
View attachment 45177
Animal data shows direct effects on growth plate chondrocytes
Halo:
(halotestin/fluoxymesterone)
View attachment 45178
Strongest/most potent androgen of the three (highly liver-toxic). Fastest bone maturation effect; FDA labels explicitly warn that androgens like this accelerate epiphyseal closure without compensatory linear growth in children. Highest risk of stunting height (if retarded)
TL;DR
Anavar increased height velocity but accelerated skeletal age more; some children lost predicted adult height (1.5–7.5 cm)
TL;DR
Winstrol affected proliferation of growth plate cells in adolescent rats (via estrogen receptor pathways). Shows direct impact on the growth plate but in a suppressed puberty model
TL;DR
Low-dose Halo increased growth velocity but required careful bone age monitoring. Final height exceeded predictions only in delayed cases
In conclusion
anavar has the most evidence for increased height velocity (despite me only showing one study for each).
however you have to be careful to not cause alot of bone maturation which isnt too hard. Best of luck
When you take any AAS even at a low dose the drug travels through your bloodstream and reaches the growth plates. There it binds directly to androgen receptors on the chondrocytes, the cartilage cells responsible for making new bone. These androgen receptors do not care if the dose is high or low; they simply respond to the presence of the molecule. Their job is to accelerate terminal differentiation, basically telling the chondrocytes to stop dividing and to mature faster into bone.
Therefore it is utter cope
for the help.
Tamoxifen
Tamoxifen:
View attachment 45173
selective estrogen receptor modulator (SERM), a drug that binds to estrogen receptors (mainly ERα and ERβ) and can act as either an estrogen blocker (antagonist) or estrogen mimic (agonist) depending on the tissue. It is FDA-approved primarily for treating and preventing estrogen receptor-positive breast cancer in adults, and it is also used off label for conditions like gynecomastia
How Tamoxifen Works
Tamoxifen competes directly with estradiol (E2) for binding to estrogen receptors in target cells
In growth-plate chondrocytes (cartilage cells responsible for bone lengthening), it can exert anti-estrogenic effects by inhibiting specific downstream signaling pathways triggered by E2, such as protein kinase C (PKC). This modulates chondrocyte differentiation and profileration
TL;DR
7 short pubertal boys (average age ~15) treated with tamoxifen (twice daily for 6 months–4 years; some also on GH). Tamoxifen significantly slowed skeletal maturation and increased predicted adult height by 4 inches (from ~5'6" to ~5'10") with no negative effects on sexual maturation or puberty progression
However authors called for larger prospective studies to confirm if this translates to actual final height gain
TL;DR
In vivo study in young male rats given clinically relevant doses for 4 weeks (followed by 14-week recovery). Tamoxifen caused persistent shorter tibia and reduced cortical bone size/strength, increased chondrocyte apoptosis, narrowed growth plates, and lowered serum IGF-1 levels
Socs2 inhibition
SOCS2:
(Suppressor of Cytokine Signaling 2)
View attachment 45174
Is a protein encoded by the SOCS2 gene in humans. It belongs to the SOCS family of intracellular proteins that act as negative feedback regulators of cytokine signaling, primarily through the JAK/STAT pathway
SOCS2 is a key negative regulator of growth hormone (GH) signaling. It binds to the phosphorylated GH receptor (GHR), promotes its ubiquitination and degradation (via the ECS ubiquitin ligase complex), and thereby dampens downstream STAT5 activation and IGF-1 production. This limits the anabolic and growth-promoting effects of GH/IGF-1
Which basically means SOCS2 is an inhibitor of GH Because SOCS2 inhibits GH signaling, reducing or blocking SOCS2 function removes this brake. This leads to enhanced GH receptor sensitivity, prolonged STAT5 signaling, higher local and systemic IGF-1, and increased linear bone growth. They are kinda like FGFR3 inhibitors.
•Significant linear growth enhancement
•Amplifies exogenous GH
•Targeted and reversible
•Metabolic risks from chronic GH/IGF-1 hyper-signaling: Potential insulin resistance,ect
IGF-1 is mitogenic; SOCS2 has complex roles in cancer (sometimes tumor-suppressive, sometimes pro-tumor in specific tissues)
•Potential organ enlargement
•Not too many ways to actually inhibit
TL;DR
mice grew 30–40% larger than wild-type, increased body weight, long-bone length, and proportional enlargement of most organs
TL;DR
Naturally occurring deletion of SOCS2 increased growth significantly however shortened lifespan in some mice
TL;DR
Mutation in SOCS2 linked to gigantism (increased height/weight) in human model
PTHrP analogues
PTHrP analogues:
View attachment 45171
Synthetic peptides that mimic parathyroid hormone-related protein (PTHrP), a key local regulator of the growth plate. The main clinically available ones are abaloparatide (Tymlos; a modified PTHrP(1-34) analogue) and teriparatide (Forteo; recombinant human PTH(1-34)). Both bind and activate the same receptor (PTH1R) that native PTHrP uses in chondrocytes, but they are given as daily subcutaneous injections.
In the epiphyseal growth plate, PTHrP is produced locally by resting-zone chondrocytes (including skeletal stem cells). It acts via PTH1R to Keep chondrocytes in the proliferative state, delay their maturation into hypertrophic cells and maintain the Ihh–PTHrP feedback loop that controls the pace of endochondral ossification
Intermittent (once-daily) dosing of PTHrP/PTH analogues mimics this natural signaling in a pulsed way that strongly stimulates bone formation meaning these compounds would:
•Expand the proliferative and hypertrophic zones
Increase chondrocyte columns and cartilage thickness
•Prolong active growth before senescence/closure
In short increasing height
Abalo and Teri Comparison:
Abalo pros:
•Designed to copy PTHrP’s natural growth-plate role more closely
•Potentially cleaner anabolic effect with less unwanted resorption or calcium spikes
•Rat data suggest stronger stimulation of cartilage thickness and site-specific bone lengthening
Abalo cons:
•Far less real-world pediatric data
osteosarcoma risk as seen in high dose rat studies
Teri pros:
•Decades more safety/efficacy data in humans
Proven to stimulate longitudinal growth in animal models
Teri cons:
•more resorption and higher hypercalcemia risk
Less selective
In conclusion abalo would be the better choice here however it has alot less research so, its down to preference.
SCO240
SCO240:
An oral small-molecule antagonist of somatostatin receptor type 5 (SSTR5). It is a first in class compound designed to stimulate endogenous GH secretion
from the pituitary gland
Somatostatin normally inhibits GH release by binding to SSTR5 on pituitary somatotroph cells. SCO-240 blocks this receptor selectively, removing the inhibition and allowing the body to release more of its own GH in a more physiological (pulsatile) pattern — without affecting other pituitary hormones (prolactin, TSH, ACTH, FSH, LH).
By boosting natural GH secretion, SCO-240 increases downstream IGF-1 production, which directly promotes chondrocyte proliferation and hypertrophy leading to increased growth velocity.
•Oral (convenience)
•Highly selective for GH
•Physiological GH release: mimics natural pulsatile pattern more closely than injected rhGH.
•Only phase 1 data in healthy adults; no published efficacy or height data in children with GHD or short stature yet.
•Basic GH excess risks (insulin resistance ect)
•Sourcing + Prices
•Limited data
TL;DR
Caused robust, dose-dependent GH secretion (comparable to therapeutic rhGH levels) with no effect on other pituitary hormones, insulin, or GLP-1.
Growth Plates
Resting Zone
This is the top layer of the growth plate, right near the end of the bone. The cells here are mostly stagnant and don’t divide much. They act like a stock of spare cartilage cells. Their job is to slowly supply new cells to the layers below when needed.
Proliferating Zone
This is the busy factory zone. The cartilage cells divide quickly and stack up in neat columns, like coins piled on top of each other. Every time they multiply, they add a bit more length to the bone. This is where most of the actual growth in height happens. It’s the most active part of the growth plate.
Hypertrophic Zone
In this zone, the cells stop dividing and start getting much bigger. As they grow larger, they help push the bone longer. Then they prepare the area by making the cartilage matrix harder. Eventually the cells die off, and the hardened cartilage gets replaced by real bone. This is the last step before the cartilage turns into solid bone.
____________________________________________________________________
Conclusion:
Leave a rep if you enjoyed
- Joined
- Oct 15, 2025
- Posts
- 3,865
- Reputation
- 5,933
and who do we have here
FS51
Gone till the summer
- Joined
- Dec 25, 2025
- Posts
- 3,829
- Reputation
- 9,356
I’m only here to read ts guide
my exams start in 6 days
- Joined
- Nov 12, 2025
- Posts
- 2,817
- Reputation
- 5,648
G
Greycel22 Elitärer Guide zu fast allem was du Wissen musst.
- Joined
- Dec 30, 2025
- Posts
- 5,934
- Reputation
- 17,809
my A2 level barely understood this jfl
- Joined
- Nov 12, 2025
- Posts
- 2,817
- Reputation
- 5,648
Dood next dm we only talking in german
Users who are viewing this thread
Similar threads
439
6K
